Response Genetics (RGDX) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 26, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	RESPONSE GENETICS INC
Entity Central Index Key	1124608
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		38,795,396
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$35,274,313

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$2,222,491	$8,148,599
Accounts receivable, net of allowance for doubtful accounts of $2,404,659 and $2,071,706 at December 31, 2013 and 2014, respectively	7,810,417	6,225,923
Prepaid expenses and other current assets	1,182,748	981,908
Total current assets	11,215,656	15,356,430
Property and equipment, net	1,406,405	1,934,582
Intangible assets, net	631,149	767,223
Other assets	191,874	0
Total assets	13,445,084	18,058,235
Current liabilities:
Accounts payable	1,609,741	1,694,312
Accrued expenses	671,906	666,675
Accrued interest	149,813	0
Accrued royalties	967,785	1,293,717
Accrued payroll and related liabilities	1,547,673	1,850,923
Capital lease obligation, current portion	100,951	157,238
Total current liabilities	5,047,869	5,662,865
Capital lease obligation, net of current portion	103,472	136,419
Line of credit	1,500,000	1,000,000
Term loan, net of debt discount of $536,150	7,963,850	0
Total liabilities	14,615,191	6,799,284
Commitments, contingencies and subsequent events (Notes 5 and 12)
Common stock classified outside of stockholders’ equity (deficit) (Note 10)	0	5,500,000
Stockholders’ equity (deficit):
Common stock, $0.01 par value; 70,000,000 shares authorized; 38,712,896 and 38,795,396 shares issued and outstanding at December 31, 2013 and 2014, respectively	388,010	337,185
Additional paid-in capital	77,698,416	70,986,406
Accumulated deficit	-78,996,541	-65,297,179
Accumulated other comprehensive loss	-259,992	-267,461
Total stockholders’ equity (deficit)	-1,170,107	5,758,951
Total liabilities, common stock classified outside of stockholders’ equity (deficit) and stockholders’ equity (deficit)	$13,445,084	$18,058,235

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts	$2,071,706	$2,404,659
Term loan net of debt discount	$536,150
Common stock, par value per share	$0.01	$0.01
Common stock, shares authorized	70,000,000	70,000,000
Common stock, shares issued	38,795,396	38,712,896
Common stock, shares outstanding	38,795,396	38,712,896

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net revenue	$16,720,327	$19,801,359
Cost of revenue	10,011,425	10,456,082
Gross Profit	6,708,902	9,345,277
Operating expenses:
Selling and marketing	5,110,076	5,421,797
General and administrative	12,876,981	10,262,623
Research and development	1,729,433	1,606,662
Total operating expenses	19,716,490	17,291,082
Operating loss	-13,007,588	-7,945,805
Other income (expense):
Interest expense	-664,727	-91,844
Interest income	0	48
Other	-27,047	17,086
Net loss	-13,699,362	-8,020,515
Unrealized gain (loss) on foreign currency translation	7,469	-3,464
Comprehensive loss	($13,691,893)	($8,023,979)
Net loss per share - basic and diluted (in dollars per share)	($0.35)	($0.24)
Weighted-average common shares - basic and diluted (in shares)	38,755,546	33,481,439

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($13,699,362)	($8,020,515)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	827,609	632,975
Amortization of loan costs and debt discounts	57,681	0
Bad debt expense	5,842,212	3,165,918
Share-based compensation - employees	776,245	474,101
Restricted stock compensation - consultants	86,250	0
Changes in operating assets and liabilities:
Accounts receivable	-7,426,707	-3,761,817
Prepaid expenses and other current assets	-205,293	-371,945
Accounts payable	-84,571	503,190
Accrued expenses	155,043	322,762
Accrued royalties	-325,932	580,941
Accrued payroll and related liabilities	-303,250	468,658
Deferred revenue	0	-483,052
Net cash used in operating activities	-14,300,075	-6,488,784
Cash flows from investing activities:
Purchase of property and equipment	-49,907	-428,487
Purchase and capitalization of software	-54,132	-179,387
Cash paid for purchase of assets	0	-200,000
Proceeds from sale of equipment	2,000	0
Net cash used in investing activities	-102,039	-807,874
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs	0	6,571,324
Proceeds from the issuance of debt, net of costs and debt discount of $386,112	8,113,888	0
Proceeds from line of credit	500,000	0
Proceeds from exercise of stock options	23,200	23,993
Capital lease payments	-168,551	-188,072
Net cash provided by financing activities	8,468,537	6,407,245
Effect of foreign exchange rates on cash and cash equivalents	7,469	-3,466
Net decrease in cash and cash equivalents	-5,926,108	-892,879
Cash and cash equivalents:
Beginning of the year	8,148,599	9,041,478
End of the year	2,222,491	8,148,599
Cash paid during the period for:
Income taxes	0	0
Interest	664,727	91,844
Supplemental disclosure of non-cash financing activities:
Equipment and software acquired under capital leases	71,317	239,150
Warrants issued with term debt	377,140	0
Assets acquired by issuance of common stock	0	980,000
Reclassification of mezzanine equity to Stockholders’ Equity (Deficit)	$5,500,000	$6,275,723

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014
Amortization of Debt Discount (Premium)	$386,112

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balances at Dec. 31, 2012	($542,211)	$232,414	$56,766,036	($57,276,664)	($263,997)
Balances (in shares) at Dec. 31, 2012		32,797,625
Exercise of stock options	23,993	180	23,813	0	0
Exercise of stock options (in shares)	18,023	18,023
Reclassification of mezzanine equity, net	6,275,723	45,619	6,230,104	0	0
Share-based compensation expense	474,101	0	474,101	0	0
Unrealized gain (loss) on foreign currency translation	-3,464	0	0	0	-3,464
Issuance of common stock	7,551,324	58,972	7,492,352	0	0
Issuance of common stock (in shares)		5,897,248
Net loss	-8,020,515	0	0	-8,020,515	0
Balances at Dec. 31, 2013	5,758,951	337,185	70,986,406	-65,297,179	-267,461
Balances (in shares) at Dec. 31, 2013		38,712,896
Issuance of restricted stock	86,250	625	85,625	0	0
Issuance of restricted stock (in shares)		62,500
Exercise of stock options	23,200	200	23,000	0	0
Exercise of stock options (in shares)	20,000	20,000
Reclassification of mezzanine equity, net	5,500,000	50,000	5,450,000	0	0
Share-based compensation expense	776,245	0	776,245	0	0
Unrealized gain (loss) on foreign currency translation	7,469	0	0	0	7,469
Issuance of warrant	377,140	0	377,140	0	0
Net loss	-13,699,362	0	0	-13,699,362	0
Balances at Dec. 31, 2014	($1,170,107)	$388,010	$77,698,416	($78,996,541)	($259,992)
Balances (in shares) at Dec. 31, 2014		38,795,396

Organization_Operations_and_Ba

Organization, Operations and Basis of Accounting	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Operations and Basis of Accounting	1. Organization, Operations and Basis of Accounting
	Response Genetics, Inc. (the “Company”) was incorporated in the State of Delaware on September 23, 1999 as Bio Type, Inc. for the purpose of providing unique molecular profiling services of tumor tissue that has been formalin-fixed and embedded in paraffin wax. In August 2000, the Company changed its name to Response Genetics, Inc.
	The Company is a life science company engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. Pharmacogenomics is the science of how an individual’s genetic makeup relates to drug response. Tests based on pharmacogenomics facilitate the prediction of a response to drug therapy or survival following surgery based on an individual’s genetic makeup. In order to generate pharmacogenomic information from patient specimens for these tests, the Company uses proprietary enabling methods for maximizing the extraction and analysis of nucleic acids and, therefore, accessing the genetic information available from each patient sample. The Company’s platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods and fluorescence in situ hybridization (“FISH”) from paraffin or frozen tissue specimens. The Company primarily derives its revenue from the sale of its ResponseDX®   diagnostic testing products and by providing pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
	The Company’s goal is to provide cancer patients and their physicians with a means to make informed, individualized treatment decisions based on genetic analysis of tumor tissues. The Company’s pharmacogenomic analysis of clinical trial specimens for the pharmaceutical industry may provide data that will lead to a better understanding of the molecular basis for response to specific drugs and, therefore lead to individualized treatment.
	Liquidity and Management’s Plans
	Since its inception, the Company has devoted substantial effort in developing its products and has incurred losses and negative cash flows from operations, and at December 31, 2013 and 2014 has an accumulated deficit of $65,297,179 and $78,996,541, respectively. The Company is forecasting continued losses and negative cash flows as it funds its sales and marketing activities and research and development programs.
	The Company’s current operating plan includes various assumptions concerning the level and timing of cash receipts from sales and cash outlays for operating expenses and capital expenditures. The Company’s ability to successfully carry out its business plan is primarily dependent upon its ability to (1) obtain sufficient additional capital, (2) attract and retain knowledgeable workers, (3) increase its cash collections and (4) generate significant additional revenues. At this time, the Company expects to satisfy its future cash needs primarily through additional financing and/or strategic alternatives. The Company is currently seeking such additional financing and/or strategic alternatives; however, there can be no assurance that any additional financing or strategic alternatives will be available on acceptable terms, if at all. If the Company is unable to timely and successfully raise additional capital, implement strategic alternatives and/or achieve profitability, it will not have sufficient capital resources to implement its business plan or continue its operations, and the Company will most likely be required to reduce certain spending and/or curtail operations, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These matters raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the accompanying financial statements to reflect any of the matters discussed above.
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company's consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Basis of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Response Genetics, Ltd., a Scottish corporation (the “Subsidiary”), which was incorporated in November 2006. The Subsidiary had no employees or active operations during 2013 and 2014. All significant intercompany transactions and balances have been eliminated in consolidation.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value due to the short-term nature and liquidity of these instruments. The Company’s cash equivalents are comprised of cash on hand, deposits in banks and money market investments.
	Accounts Receivable
	Pharmaceutical Accounts Receivable
	The Company invoices its clients as specimens are processed and any other contractual obligations are met. The Company’s contracts with clients typically require payment within 45 days of the date of invoice. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its clients to make required payments. The Company specifically analyzes accounts receivable and historical bad debts, client credit, current economic trends and changes in client payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. To date, the Company’s clients have primarily been large pharmaceutical companies. As a result, bad debts from clinical accounts receivable to date have been minimal. Pharmaceutical company accounts receivable as of December 31, 2013 and 2014 were $1,892,384 and $1,037,834 respectively.  There were no allowances for doubtful accounts recorded against these pharmaceutical accounts receivable at December 31, 2013 and 2014.
	ResponseDX® Accounts Receivable
	ResponseDX® accounts receivable are recorded from two primary payors: Medicare and third party/private payors (“Private Payors”).  ResponseDX® accounts receivable are recorded at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors.  Management performs ongoing valuations of accounts receivable balances based on management’s evaluation of historical collection experience and industry trends.  Based on the historical experience for the Company’s  accounts, management has determined, based on a detailed analysis, that accounts receivable associated with certain billings are unlikely to be collected.  Therefore, the Company has recorded an allowance for doubtful accounts of $2,404,659 and $2,071,706 as of December 31, 2013 and 2014. The Company’s bad debt expense for the years ended December 31, 2013 and 2014 was $3,165,918 and $5,842,212, respectively.
	ResponseDX® accounts receivable consisted of the following:
		December 31,		December 31,
		2013		2014
	Net Medicare receivable	$	2,422,611	$	2,814,989
	Net Private Payor receivable		4,315,587		6,029,300
			6,738,198		8,844,289
	Allowance for doubtful accounts		-2,404,659		-2,071,706
		$	4,333,539	$	6,772,583
	As more fully discussed in Note 3 Property and Equipment and Intangible Assets, the Company acquired accounts receivable in August 2013 that had a valuation of $257,000. All of these receivables were collected by December 31, 2013.
	As part of its process for evaluating the collectability of aged accounts receivable management identified delays in the Medicare administrative law appeal process for aged accounts receivable that would extend the process significantly (up to two years). Accordingly, management considered this factor in estimating the allowance for doubtful accounts and concluded that an additional allowance of approximately $690,000 was necessary as of December 31, 2013 to reserve for the balance of Medicare accounts receivable as of December 31, 2013 that were going to age greater than one year shortly after December 31, 2013. At December 31, 2014 all Medicare accounts receivable outstanding greater than one year have been reserved 100%.
	Property and Equipment and Intangible Assets
	Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows:
	Laboratory equipment	5 to 7 years
	Furniture and equipment	5 to 7 years
	Purchased and internally-developed software	3 to 5 years
	Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term
	Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. The Company has capitalized costs related to the development of database software (see Note 3). The portion of this database placed into service is amortized in accordance with ASC 350-40, Internal-Use Software. The amortization period is five years using the straight-line method.
	Revenue Recognition
	Pharmaceutical Revenue
	Revenues that are derived from testing services provided to pharmaceutical companies are recognized on a contract specific basis pursuant to the terms of the related agreements. Revenue is recognized in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
	Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through the Company’s laboratory under a specified contractual protocol and are recorded on the date the tests are resulted. Certain contracts have minimum assay requirements that, if not met, result in payments that are due upon the completion of the designated period. In these cases, revenues are recognized when the end of the specified contract period is reached.
	On occasion, the Company may enter into a contract that requires the client to provide an advance payment for specimens that will be processed at a later date. In these cases, the Company records this advance as deferred revenue and recognizes the revenue as the specimens are processed or at the end of the contract period, as appropriate. There was no deferred revenue at December 31, 2013 or December 31, 2014.
	In March 2010, the Company entered into a non-exclusive license agreement with GlaxoSmithKline, LLC, which called for certain milestone payments to be made to the Company when certain events specified in the agreement occur, specifically GlaxoSmithKline, LLC submitting an application to use the license to the FDA, the FDA approving the application, and issuance of certain patent applications to the Company. The Company has no further obligations related to these events and therefore has recorded the milestone payments that were due under the agreement into revenue at the time the event occurred. Milestone payments received in 2013 and 2014 were $1,000,000 and $-0-, respectively.
	The Company recorded net revenue from pharmaceutical clients of $7,789,985 and $2,124,130 for the years ended December 31, 2013 and 2014, respectively.
	ResponseDX® Revenue
	The Company recognizes revenues when (a) the price is fixed or determinable, (b) persuasive evidence of an arrangement exists, (c) the service is performed and (d) collectability of the resulting receivable is reasonably assured. The Company’s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent and revenues are recognized once the diagnostic services have been performed, and the results have been delivered to the ordering physician.
	Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, commercial insurance plans and Medicare programs. Billings for services under third-party payer programs are included in revenue net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated payment amounts.  Significant judgment is inherent in the selection of assumptions and the interpretation of historical experience as well as the identification of external and internal factors affecting the determination of these reserves for Medicare, private health insurance companies, healthcare institutions, and patients. The Company reports revenues from contracted payers, including Medicare, certain insurance companies and certain healthcare institutions, based on the contractual rate, or in the case of Medicare, published fee schedules. The Company reports revenues from non-contracted payers, including certain insurance companies and individuals, based on the amount expected to be collected. The difference between the amount billed and the amount estimated to be collected from non-contracted payers is recorded as a contractual allowance to arrive at the reported net revenues. The expected revenues from non-contracted payers are based on the historical collection experience of each payer or payer group, as appropriate.The assumptions used to determine these contractual allowances are reasonable considering known facts and circumstances. If actual future payments are less than the estimates the Company made at the time of recognizing revenue, the consolidated financial position, results of operations and cash flows may be negatively impacted. If actual future payments are materially different from the contracted amounts or estimates, the difference is accounted for as a change in estimate in the period in which they become known. Adjustments to the estimated payment amounts based on final settlement are recorded upon settlement as an adjustment to revenue. In 2014 and 2013, approximately 38% and 33.5%, respectively, of the Company's revenues were derived directly from the Medicare program. The Company’s Medicare provider number allows it to invoice and collect from Medicare. The Company’s invoicing to Medicare is primarily based on amounts allowed by Medicare for the service provided as defined by Common Procedural Terminology (“CPT”).   Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation.
	The following details ResponseDX® revenue for the years ended December 31, 2013 and 2014:
		Year Ended December 31,
		2013		2014
	Net Medicare revenue	$	4,521,732	$	4,886,507
	Net Private Payor revenue		7,489,642		9,709,690
	Net ResponseDX® revenue	$	12,011,374	$	14,596,197
	The Company recognizes revenue for services covered by Medicare based on the Medicare fee schedule. The Company’s fees for January to October 2013 were based the 2013 initial annual Medicare fee schedule. From October 2013 through December 2013, the fees were based on Centers for Medicare and Medicaid Services (“CMS”) updated payment rates for some, but not all of the Common Procedural Terminology (“CPT”) codes used by the Company. For the remaining CPTs not covered by the CMS update, the Company used the Medicare fees provided by the local Medicare Administrative Contractor proposed reimbursement rates. For 2014, the Company’s Medicare fees were based on the Centers for Medicare and Medicaid Services (“CMS”) proposed “Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule, Clinical Laboratory Fee Schedule & Other Revisions to Part B for CY 2014” released in July 2013.
	The Company updates its estimates of Medicare fees based on current information from CMS. The nature of the testing services the Company provides, the evidence the Company gathers to establish the creditworthiness of its payors and the delivery method of its services have not changed from prior periods, and therefore these assumption remain appropriate.
	Cost of Revenue
	Cost of revenue represents the cost of materials, direct labor, royalties, costs associated with processing tissue specimens including pathological review, staining, microdissection, paraffin extraction, reverse transcription polymerase chain reaction, fluorescence in situ hybridization (“FISH”), quality control analyses, license fees and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.
	License Fees
	The Company has licensed technology for the extraction of ribonucleic acid (“RNA”) from formalin-fixed, paraffin-embedded tumor specimens from the University of Southern California (“USC”). Under the terms of the license agreement, the Company is required to pay royalties to USC calculated as a fixed percentage of net sales price as defined in the agreement that the Company generates by using this technology. Total license fees expensed in cost of revenue under the license agreement with USC were $305,616 for the year ended December 31, 2013 and $42,289 for the year ended December 31, 2014. In addition, in the year ended December 31, 2014, the Company recorded credits to the royalty expense of $240,077 in each of the third and fourth quarters, representing, in the aggregate, a one-time $480,154 adjustment for the period over-accruals resulting from a change in the estimate of royalty expense. The net credit of $437,865 is included in our cost of revenue.  The Company also maintains a non-exclusive license to use certain patents related to the polymerase chain reaction (“PCR”) of Roche Molecular Systems, Inc. (“Roche”). The Company pays Roche a royalty fee based on revenue that the Company generates through use of this technology. The Company accrues for such royalties at the time revenue is recognized. Royalties expensed in cost of revenue under the Roche agreement totaled $280,325 and $211,932 for the years ended December 31, 2013 and 2014, respectively. Such royalties are included in cost of revenues in the accompanying statements of operations.
	Royalty expense is based on a fixed percentage of net sales price as defined in the agreement of specific tests pursuant to terms set forth in the agreements with USC and Roche. The amount due is calculated based on the revenue the Company recognizes using the respective licensed technology. The royalty expense recognized, like the associated revenue, depends on the timing of the specimens submitted by the Company’s clients for testing.
	Additionally, the Company periodically analyzes the technical procedures performed in its test offerings to assess which activities utilize licensed technologies and to calculate royalties for use of the licensed technology. The most recent analyses indicate that the Company could owe less than the amounts that have been accrued for royalties payable and based on the Company’s discussions with USC, the Company has taken a credit for its USC royalties over-accrual. Roche is still reviewing the Company’s updated royalty calculations. It is possible that based on Roche’s review and the Company’s discussions with Roche, the Company may further adjust its Roche royalty accrual.
	Research and Development
	The Company expenses costs associated with research and development activities as incurred. Research and development costs are expensed as incurred and classified as research and development costs. Research and development costs include employee costs (salaries, payroll taxes, benefits, and travel), equipment depreciation and maintenance, laboratory supplies, primers and probes, reagents, patent costs and occupancy costs.
	Line of Credit
	On July 14, 2011, the Company entered into a line of credit agreement with Silicon Valley Bank (the “Bank”). The agreement has been amended most recently on July 30, 2014, as discussed below. The line of credit is collateralized by all of the Company’s assets including its pharmaceutical, Private Payor and Medicare receivables. The amended maximum amount that can be borrowed from the credit line is $2,000,000. As of December 31, 2013 and 2014, the amount the Company can draw from the loan was $1,000,000 and $500,000, respectively, calculated as the lesser of (i) the Company’s calculated borrowing base, which was 80% of certain of the Company’s accounts receivable, or (ii) the amount available under the credit line. As of December 31, 2013, the interest fees associated with this line of credit were set at the prime rate plus 1%.  Effective with the July 30, 2014 amendment to this credit agreement, the interest rate was set at prime plus 2.25%. During 2013 and the first half of 2014, the rate charged to the Company was 5%. For the latter half of 2014 the rate charged to the Company was 5.5%. As needed from time to time, the Company may draw on this line for use for general corporate purposes. As of December 31, 2013 and December 31, 2014, the Company has drawn $1,000,000 and $1,500,000 against the line of credit. The line of credit is subject to various financial covenants. In 2013 the Company was in violation of certain of these covenants and, pursuant to an amendment on March 7, 2013, the Bank waived the Company's existing breach of financial covenants under the credit agreement and the parties restructured the line of credit to provide that, among other things: (i) the revolving line of credit's maturity date was extended to March 7, 2015, (ii) the fee for the unused portion of the revolving line of credit was reduced from 0.375% to 0.250% per annum of the average unused portion of the revolving line of credit, (iii) the Company must continue to meet certain reporting requirements including providing financial statements and a certificate of compliance with the terms and conditions of the credit agreement by an authorized officer to the Bank within 45 days of the last day of each calendar quarter, provided that if the Company has less than $4,000,000 in its account at the Bank at any time during such calendar quarter, the Company must provide the financial statements and the certificate of compliance within 30 days of the end of such calendar quarter and provide a monthly report on revenues realized from private payors, (iv) the financial covenants were amended and restated to require the Company to maintain a ratio of quick assets to current liabilities of 1:50 to 1:00 and meet certain specified minimum adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) requirements as defined in the amendment and measured on a monthly basis and (v) the Bank is granted certain additional inspection of books, records and collateral rights.
	On July 30, 2014, the Bank waived several additional covenant violations and amended the credit agreement to provide, among other things: (i) an increase in the interest rate to prime plus 2.25%; (ii) the addition of an “Early Termination Fee” of $40,000; (iii) an adjusted quick ratio of at least 1.25 to 1.00; (iv) permission for the Company to receive up to $12,000,000 from a third party term loan; (v) a requirement that the Company maintain quarterly rolling twelve-month net revenue balances beginning December 31, 2014; and (vi) a requirement that the Company maintain quarterly minimum liquidity of $1,000,000 and (vii) an extension of the revolving line of credit's maturity date to July 25, 2016. At December 31, 2014 the Company was in compliance with these covenants.
	As of December 31, 2013 and 2014, the line of credit under the credit agreement was classified as a non-current liability of the Company on the accompanying balance sheet as the line of credit had a maturity date of greater than one year.
	From time to time, the Company’s calculated borrowing base under its Bank line of credit may decrease to a level where the Company is in an over-advance position in which case the Company will be required to repay any outstanding amounts greater than the calculated borrowing base for such covered period back to the Bank immediately. The Company will be able to draw down on the credit line again with respect to such paid back amount once the Company is in compliance with the borrowing base requirement.
	SWK Term Loan
	On July 30, 2014 (the “Closing Date”), the Company entered into a credit agreement (the “SWK Credit Agreement”) with SWK Funding LLC, as the administrative agent (the “Agent” or “SWK”), and the lenders (including SWK) party thereto from time to time (the “Lenders”). The SWK Credit Agreement provides for a multi-draw term loan to the Company (the “Loan”) up to a maximum principal amount of $12,000,000 (the “Loan Commitment Amount”). On the Closing Date, the Lenders advanced the Company an amount equal to $8,500,000 which is due and payable on July 30, 2020 (the “Term Loan Maturity Date”) or such earlier date on which the Loan Commitment Amount is terminated pursuant to the terms of the SWK Credit Agreement. On February 3, 2015 (the “Amendment Closing Date”), the Company and SWK entered into a first amendment (the “Amendment”) to the SWK Credit Agreement.  Pursuant to the Amendment, the Company drew an additional $1,500,000 of the Loan Commitment Amount increasing the total amount advanced to the Company under the SWK Credit Agreement to $10,000,000.
	The Loan bears interest at a rate equal to the LIBOR Rate (as defined in the SWK Credit Agreement) plus an applicable margin of 12.5% per annum, subject to a one percent (1.0%) LIBOR floor. Interest on the Loan is due and payable in arrears (i) on the forty-fifth (45th) day following the last calendar day of each of the months of September, December, March, and June, commencing on November 15, 2014, (ii) upon a prepayment of the Loan and (iii) on the Term Loan Maturity Date. At December 31, 2014, the interest rate charged to the Company was 13.5%. Upon the earlier of (a) the Term Loan Maturity Date or (b) full repayment of the Loan, the Company is also required to pay an exit fee.
	On September 9, 2014, SWK, in its capacity as the initial Lender, assigned part of its interests under the SWK Credit Agreement to SG-Financial, LLC (“SG”). Pursuant to the assignment, SG was assigned $2,500,000 of the $8,500,000 Closing Date initial advance to the Company and $1,029,412 of the subsequent term loan commitment. Pursuant to the assignment, as of the effective date of the assignment, SG became a party to the SWK Credit Agreement as a Lender. On January 30, 2015, SG assigned all of its interests under the SWK Credit Agreement to SWK. As such, as of January 30, 2015, SWK is the sole Lender under the SWK Credit Agreement.
	On the Closing Date, the Company issued to the Agent a warrant (the “Initial Warrant”) to purchase up to 681,090 shares of the Company's common stock. The Initial Warrant was exercisable, in whole or in part, from the date of issuance until and including July 30, 2020 at an exercise price of $0.936 per share, and was subject to customary adjustments for stock splits, stock dividends, recapitalization and the like. The relative fair value of the Initial Warrant was $377,140, or approximately $0.55 per covered share, using a Black-Scholes pricing model with the following assumptions: 2.01% risk free rate, 0% dividend, 101.5% volatility, and six-year expected life. The value of the warrant was recorded on the balance sheet included in additional paid-in capital. On September 9, 2014, the Agent assigned a portion of the Initial Warrant consisting of the right to purchase 200,321 shares of common stock to SG (the “SG Initial Warrant”). On January 30, 2015, SG assigned the SG Initial Warrant back to the Agent and on the Amendment Closing Date, the Company replaced the Initial Warrant to purchase the total 681,090 shares of the Company’s common stock with a new warrant with an adjusted exercise price (the “Replacement Warrant”).   The Replacement Warrant is exercisable up to and including July 30, 2020 at an exercise price of $0.39 per share.  The Agent may exercise the Replacement Warrant on a cashless basis at any time.  In the event the Agent exercises the Replacement Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the Replacement Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	In addition, on the Amendment Closing Date, the Company issued the Agent a new warrant (the “First Amendment Warrant”) to purchase 576,923 shares of Common Stock.  The First Amendment Warrant is exercisable up to and including February 3, 2021 at an exercise price of $0.39 per share, subject to adjustment.  The Agent may exercise the First Amendment Warrant on a cashless basis at any time.  In the event the Agent exercises the First Amendment Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the First Amendment Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
For accounting purposes, the proceeds received pursuant to the SWK Credit Agreement were allocated to the liability for debt, a debt issuance discount and additional paid-in capital for the Initial Warrant based upon the relative fair value of the loan and the Initial Warrant. The amounts recorded in the financial statements were $8,500,000 for loan liability, $576,161 for debt issuance discount and $377,140 to additional paid-in capital for the Initial Warrant. Additionally, the Company recorded deferred loan issuance costs of $187,092 for investment banker fees and legal fees incurred to enter into the SWK Credit Agreement. The debt issuance discount and the deferred issuance costs are being amortized to interest expense over the six-year term of the loan.
The remaining $2,000,000 of the Loan Commitment Amount (the “Subsequent Term Loan”) may be advanced to the Company upon written request to the Agent during the period beginning on the Amendment Closing Date and ending February 28, 2016 provided that (i) no default or event of default has occurred or is continuing under the SWK Credit Agreement, (ii) the aggregate revenue recognized by the Company and any of its subsidiaries during any period of four (4) consecutive fiscal quarters ending prior to December 31, 2015 exceeds a certain dollar amount threshold and (iii) the Agent has received an executed warrant (the “Subsequent Term Loan Warrant”) to purchase a number of shares of common stock equal to the number obtained when the amount of the Subsequent Term Loan is multiplied by 15% and the product is divided by the exercise price of such warrant. The exercise price of the Subsequent Term Loan Warrant will be equal to the lower of (a) the average closing price of the common stock on the previous 5 trading days before the closing date of the Subsequent Term Loan, or (b) the closing price of the common stock on the last trading day prior to such Subsequent Term Loan’s closing date. The Subsequent Term Loan Warrant will be exercisable for a period of six years from the closing date of the Subsequent Term Loan, subject to adjustment. Upon issuance, the Agent may exercise the Subsequent Term Loan Warrant on a cashless basis at any time. In the event the Lender exercises the Subsequent Term Loan Warrant on a cashless basis, the Company will not receive any proceeds. The exercise price of the Subsequent Term Loan Warrant is subject to customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like.
The Company may prepay the Loan, in whole or in part, upon five business days’ written notice provided that a prepayment premium is paid to the Lenders as set forth in the SWK Credit Agreement. The Company is required to prepay the Loan with any net cash proceeds received from certain types of dispositions of assets described in the SWK Credit Agreement. The Company is also required to make certain revenue-based payments on the Company’s quarterly revenues, applied in the following priority: (i) first, to the payment of all fees, costs, expenses and indemnities due and owing to the Agent under the SWK Credit Agreement, (ii) second, to the payment of all fees, costs, expenses and indemnities due and owing to the Lenders under the SWK Credit Agreement, (iii) third, to the payment of all accrued but unpaid interest until paid in full, (iv) fourth, for each revenue-based payment date after August 2016, to the payment of all principal of the Loan up to an aggregate amount of $750,000 on any such payment date and (v) fifth, all remaining amounts to the Company.
As of December 31, 2014, the term debt under SWK Credit Agreement was classified as a non-current liability of the Company on the accompanying balance sheet as the repayment terms are based on future revenues that cannot be reasonably estimated and therefore all outstanding amounts are classified as non-current.
The SWK Credit Agreement contains customary affirmative and negative covenants for credit facilities of its type, including covenants that limit the Company’s ability to pay dividends or redeem outstanding equity interests, incur additional indebtedness, grant additional liens, engage in any other type of business, make investments, merge, consolidate or sell all or substantially all of its assets and enter into transactions with related parties. The SWK Credit Agreement also contains certain financial covenants, including certain minimum aggregate revenue requirements. The Company was in compliance with these covenants at December 31, 2014.
The SWK Credit Agreement includes customary events of default, including failure to pay principal, interest or fees when due, failure to comply with covenants, default under certain other indebtedness, certain insolvency or bankruptcy events, the occurrence of certain material judgments, the institution of any proceeding by a government agency or a change of control of the Company that it is not otherwise permitted under the SWK Credit Agreement.
Income Taxes
Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of December 31, 2013 and 2014, the Company does not have a liability for unrecognized tax benefits. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision, and the Company includes accrued interest and penalties with the related tax liability in the balance sheet. For the years ended December 31, 2013 and 2014, there were no interest or penalties recorded on the consolidated statement of operations.
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation, Share-Based Payment. Stock-based compensation expense for all stock-based compensation awards granted is based on the grant-date fair value estimated in accordance with the provisions of ASC 718.  The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting period. As further described in Note 7, certain awards granted to Thomas A. Bologna, the Company’s Chairman and Chief Executive Officer, were recognized based on an accelerated vesting basis triggered by market conditions rather than a straight-line basis.
The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, Equity. Under ASC 505, stock option awards issued to non-employees are measured at fair value using the Black-Scholes option-pricing model and recognized pursuant to a performance model.
Management Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates in these consolidated financial statements have been made for revenue, allowances for doubtful accounts, impairment of long-lived assets, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
Long-lived Assets
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates potential impairment by comparing the carrying amount of the asset with the estimated undiscounted future cash flows associated with the use of the asset and its eventual disposition. Should the review indicate that the assets cost is not recoverable, the carrying value of the asset would be reduced to its fair value, which is measured by future discounted cash flows.
Foreign Currency Translation
The financial position and results of operations of the Company’s foreign subsidiary are determined using local currency as the functional currency. Assets and liabilities of these operations are translated at the exchange rate in effect at each period-end. Statement of Operations amounts are translated at the average rate of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in stockholders’ equity (deficit).
Comprehensive Loss
The components of comprehensive loss are net loss and foreign currency translation adjustments for the years ended December 31, 2013 and 2014.
Fair Value of Financial Instruments
Cash and cash equivalents are stated at cost, which approximates fair market value.  Cash equivalents consist of money market accounts, with fair values estimated based on quoted market prices. Debt balances are stated at historical amounts less principal payments, which approximate fair market value. The Company believes interest rates in its debt agreements are commensurate with lender risk profiles for similar companies.
Advertising costs
The Company markets its services through its advertising activities in trade publications and on the internet. Advertising costs are included in selling and marketing expenses on the statements of operations and are expensed as incurred.  Advertising costs for the years ended December 31, 2013 and 2014 were $16,677 and $62,793, respectively.
Concentration of Credit Risk Clients and Limited Suppliers
Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. At December 31, 2013 and 2014, the Company had $7,726,681 and $1,960,623 in cash and cash equivalents that exceeded federally insured limits. At December 31, 2013 and 2014, $6,969 and $6,571 of cash was held outside of the United States.
Revenue sources that accounted for greater than 10 percent of revenue are provided below (* indicates amount is below 10%):
	Year Ended December 31,
	2013					2014
			Percent of					Percent of
			Total					Total
	Revenue		Revenue			Revenue		Revenue
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	1,134,366		5.8	%	$	174,597		*	%
GlaxoSmithKline Biologicals S.A.	$	3,534,619		17.9	%	$	1,287,184		*	%
Total GlaxoSmithKline entities	$	4,668,985		23.7	%	$	1,461,781		*	%
Medicare, net of contractual allowances	$	4,521,732		22.8	%	$	4,886,507		29.2	%
Clients that accounted for greater than 10 percent of gross accounts receivable are provided below (* indicates amount is below 10%):
	As of December 31,
	2013					2014
			Percent of					Percent of
	Receivable		Gross			Receivable		Gross
	Balance		Receivables			Balance		Receivables
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	597,937		6.9	%	$	174,547		*	%
GlaxoSmithKline Biologicals S.A.	$	544,298		6.3	%	$	588,212		*	%
Total GlaxoSmithKline entities	$	1,142,235		13.2	%	$	762,759		*	%
Medicare, net of contractual allowances	$	2,422,611		28.1	%	$	2,814,989		28.5	%
Many of the supplies and reagents used in the Company’s testing process are procured from a limited number of suppliers. Any supply interruption or an increase in demand beyond the suppliers’ capabilities could have an adverse impact on the Company’s business. Management believes it can identify alternative sources, if necessary, but it is possible such sources may not be identified in sufficient time to avoid an adverse impact on its business. Refer also to Note 6 for further discussion regarding these supply agreements. The Company purchases certain laboratory supplies and reagents primarily from a limited number of suppliers. The Company made approximately 87% of its reagent purchases from four suppliers during the year ended December 31, 2013 and made approximately 73% of its reagent purchases from three suppliers during the year ended December 31, 2014.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which modifies how all entities recognize revenue, and consolidates into one Accounting Standards Codification ("ASC") Topic (ASC Topic 606, Revenue from Contracts with Customers) the current guidance found in ASC Topic 605, Revenue Recognition, and various other revenue accounting standards for specialized transactions and industries. The core principle of the guidance is that “an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” In achieving this objective, an entity must perform five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations of the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 also clarifies how an entity should account for costs of obtaining or fulfilling a contract in a new ASC Subtopic 340-40, Other Assets and Deferred Costs – Contracts with Customers.
ASU 2014-09 is effective for public companies for annual periods beginning after December 15, 2016 and interim periods within those annual periods, and early adoption is not permitted. ASU 2014-09 may be applied using either a full retrospective approach, in which all years included in the financial statements are presented under the revised guidance, or a modified retrospective approach. Under the modified retrospective cumulative catch-up approach, financial statements will be prepared using the new standard for the year of adoption, but not for prior years. Under this method, entities will recognize a cumulative catch-up adjustment to the opening balance of retained earnings at the effective date for contracts that still require performance by the company and disclose all line items in the year of adoption as if they were prepared under the old revenue guidance. The Company is currently evaluating the impact of ASC 606, but at the current time does not know what impact the new standard will have on revenue recognized and other accounting decisions in future periods, if any, nor what method of adoption will be selected if the impact is material.
In August 2014, the Financial Accounting Standards Board issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-09”). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there is substantial doubt about a company's ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company's ability to continue as a going concern within one year from the date the financial statements are issued. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter; earlier adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial condition, results of operations or cash flows.

Property_and_Equipment_and_Int

Property and Equipment and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment and Intangible Assets	3. Property and Equipment and Intangible Assets
	Property and equipment consists of the following:
		December 31,		December 31,
		2013		2014
	Laboratory equipment	$	4,468,055	$	4,543,019
	Furniture and equipment		736,886		762,466
	Leasehold improvements		487,843		496,523
			5,692,784		5,802,008
	Less: Accumulated depreciation		-3,758,202		-4,395,603
	Total property and equipment, net	$	1,934,582	$	1,406,405
	Purchased software	$	749,587	$	803,719
	Internally developed software		213,361		213,361
	Trademarks		33,000		33,000
			995,948		1,050,080
	Less: Accumulated amortization		-228,725		-418,931
	Total intangible assets, net	$	767,223	$	631,149
	Intangible assets are carried at the cost to obtain them. Internally developed intangible assets are amortized using the straight-line method over the estimated useful life of five years. During the first quarter of 2013, the Company deployed its new Laboratory Information Management System (“LIMS”) and began amortizing the cost.
	Depreciation and amortization expense, included in general and administrative expenses for the years ended December 31, 2013 and 2014 was $632,975 and $827,609, respectively.
	On August 23, 2013, the Company entered into an asset purchase agreement (the “Pathwork Purchase Agreement”) with Pathwork (assignment for the benefit of creditors), LLC (“Seller”), pursuant to which the Company acquired substantially all of the assets of Pathwork Diagnostics, Inc. (“Pathwork”), which had previously assigned all of its assets to Seller for the benefit of its creditors pursuant to a General Assignment, dated as of April 2, 2013.  Pursuant to the Pathwork Purchase Agreement, the Company acquired all intellectual property, know-how, data, equipment and materials formerly owned by Pathwork which relate to its FDA-cleared Tissue of Origin cancer test. Management evaluated the assets acquired from Seller and concluded the combined assets did not meet the definition of a business, primarily because the necessary processes were not acquired.  Accordingly, the Company accounted for the transaction as a basket purchase of assets in which the purchase price was allocated to the individual assets acquired based upon relative fair value.
	The Company acquired the assets for the following consideration: (i) an aggregate of 500,000 newly-issued registered shares of the Company’s common stock issued to two senior secured creditors of Pathwork which were designated by Seller in the Pathwork Purchase Agreement and (ii) a cash payment of $200,000 to Seller.
	Based upon a valuation of the acquired Pathwork assets, the purchase price was allocated as follows: $257,000 to accounts receivable, $785,000 to laboratory equipment, and $138,000 to internally developed software and other intangible assets. The Company launched the Pathwork acquired Tissue of Origin test commercially as its ResponseDX: Tissue of Origin® test in February 2014. Therefore, depreciation and amortization of these assets began during the first quarter of 2014 over their expected useful lives, which are approximately five years.
	Expected future amortization of intangible assets over the next five years ending December 31 is as follows: $193,926 in 2015, $179,887 in 2016, $160,028 in 2017, $59,413 in 2018 and $4,895 thereafter.
	Capital Leases
	The Company leases certain equipment and related software that is recorded as capital leases. This equipment and software is included in property and equipment on the accompanying balance sheet as of December 31, 2013 and 2014 as follows:
		2013		2014
	Equipment and software financed under capital leases	$	584,150	$	655,467
	Less: Accumulated amortization		-320,769		-472,679
	Equipment and software financed under capital leases, net	$	263,381	$	182,788
	Future minimum lease payments under capital leases as of December 31, 2014 are as follows:
	Years ending December 31,
	2015	$	129,154
	2016		68,792
	2017		16,364
	2018		16,364
	Thereafter		9,546
	Total minimum lease payments		240,220
	Less amount represented by interest		-35,797
	Less current portion		-100,951
	Capital lease obligation, net of current portion	$	103,472

Loss_Per_Share

Loss Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Loss Per Share	4. Loss Per Share
	The Company calculates net loss per share in accordance with ASC 260, Earnings Per Share. Under the provisions of ASC 260, basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. Common stock equivalents consist of shares of common stock issuable upon the exercise of stock options.
	The following table sets forth the computation for basic and diluted loss per share:
		Year Ended December 31,
		2013		2014
	Numerator:
	Net loss	$	-8,020,515	$	-13,699,362
	Numerator for basic and diluted earnings per share	$	-8,020,515	$	-13,699,362
	Denominator:
	Denominator for basic and diluted earnings per share — weighted-average shares outstanding		33,481,439		38,755,546
	Basic and diluted loss per share	$	-0.24	$	-0.35
	Outstanding stock options to purchase 2,288,076 and 2,833,604 shares for the years ended December 31, 2013 and 2014, respectively, were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive. Outstanding warrants and restricted stock units of 681,090 and 270,000 were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive at December 31, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies
	Operating Leases
	The Company leases 27,446 square feet of office and laboratory space in Los Angeles, California, under a non-cancelable operating lease that was amended on February 3, 2014 to, among other things, extend the term of the lease to June 30, 2015. The Company had the option to extend the lease to June 30, 2016 which option the Company exercised on February 26, 2015.
	Rent expense, which is classified in cost of revenue, general and administrative, and research and development expenses was $683,926 and $841,309 for the years ended December 31, 2013 and 2014, respectively.
	Future minimum lease payments by year and in the aggregate due under noncancelable operating leases for facilities, equipment and software as a service, consist of the following at December 31, 2014:
	Years Ending December 31,
	2015	$	582,018
	2016		35,807
	Total	$	617,825
	Guarantees
	The Company enters into indemnification provisions under its agreements with other counterparties in its ordinary course of business, typically with business partners, clients and landlords. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company's activities. These indemnification provisions generally survive termination of the underlying agreement. The Company reviews its exposure under these agreements no less than annually, or more frequently when events require. The Company believes the estimated fair value of these agreements is minimal as, historically, no payments have been made by the Company under these indemnification obligations. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2013 and December 31, 2014.
	Legal Matters
	The Company is, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. Reserves are established for specific liabilities in connection with legal actions when they can be deemed probable and estimable. These matters are not expected to have a material adverse effect upon the Company’s financial condition.
	Employment Agreements
	The Company has employment contracts with several individuals, which provide for annual base salaries and potential bonuses. These contracts contain certain change of control, termination and severance clauses that require the Company to make payments to certain of these employees if certain events occur as defined in their respective contracts.

License_and_Collaborative_Agre

License and Collaborative Agreements	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License and Collaborative Agreements	6. License and Collaborative Agreements
	License Agreement with the University of Southern California (“USC”)
	In April 2000, as amended in June 2002 and April 2005, the Company entered into a license agreement with USC. Under this agreement, USC granted the Company a worldwide, exclusive license with the right to sublicense, the patents for nucleic acid extraction methodologies (“RGI-1”) and related technology, for use in human and veterinary diagnostic laboratory services, the sale of clinical diagnostic products, and the sale of research products to the research community. USC retains the right under the agreement to use the technology for research and educational purposes.
	In consideration for this license, the Company agreed to pay USC royalties based on a percentage of net sales of products or services that make use of RGI-1 and related technology and to meet a certain minimum in royalty payments.   Royalty expense relating to this agreement amounted to $305,616 and $42,289 for the years ended December 31, 2013 and 2014, respectively.  In addition, in the year ended December 31, 2014, the Company recorded credits to the royalty expense of $240,077 in each of the third and fourth quarters, representing, in the aggregate, a one-time $480,154 adjustment for prior period over-accruals resulting from a change in the estimate of the royalty expense. The net credit of $437,865  is included in cost of revenue in the accompanying statements of operations.
	License Agreement with Roche Molecular Systems (“Roche”)
	In November 2004, the Company entered into a non-exclusive license to use Roche’s technology including specified nucleic acid amplification processes (“PCR Processes”) to perform certain human invitro clinical laboratory services. In consideration for this license, the Company is obligated to pay royalties to Roche, based on a percentage of net sales of products or services that make use of the PCR Processes. Royalty expense included in cost of revenue relating to this agreement amounted to $280,325 and $211,932 for the years ended December 31, 2013 and 2014, respectively.
	In November 2004, the Company also entered into an agreement with Roche, pursuant to which the Company is collaborating with Roche to produce commercially viable assays used in the validation of genetic markers for pharmaceutical companies. Specifically, the Company has licensed the rights to Roche to use the pre-diagnostic assays the Company develops in the course of using its RNA-extraction technologies to provide testing services to pharmaceutical companies and to produce diagnostic kits that then can be sold commercially to those pharmaceutical companies. Roche is required to pay the Company royalties of a certain percentage of net sales of such diagnostic kits sold to pharmaceutical companies. Through December 31, 2014, Roche has not been required to pay any royalties to the Company pursuant to this agreement.
	Services Agreement with Taiho Pharmaceutical Co., Ltd. (“Taiho”)
	In July 2001, the Company entered into an agreement with Taiho pursuant to which the Company provided Taiho with RGI-1 generated molecular-based tumor analyses for use in guiding chemotherapy treatment for cancer patients and for use in Taiho’s business of developing and marketing pharmaceutical and diagnostic products for use against cancer. The agreement was subsequently amended and extended through December 31, 2013. The agreement was not renewed or amended for 2014. Revenue recognized under this agreement for the years ended December 31, 2013 and 2014 was $950,000 and $-0-, respectively.
	Services Agreement with GlaxoSmithKline, LLC formerly known as SmithKline Beecham Corporation (d.b.a. GlaxoSmithKline or “GSK”)
	In January 2006, the Company entered into a master services agreement with GSK, a leading pharmaceutical manufacturer, pursuant to which the Company provides services in connection with profiling the expression of various genes from a range of human cancers. Under the agreement, the Company provides GSK with testing services as described in individual protocols and GSK pays the Company for such services based on the pricing schedule established for each particular protocol. GSK is obligated to make minimum annual payments to the Company under the agreement and also was obligated to make a non-refundable upfront payment to the Company, to be credited against work undertaken pursuant to the agreement.
	In December 2008, the Company amended and restated its master services agreement with GSK and extended the term of the agreement for a two-year period, with the option for the parties to extend the agreement for additional one-year periods at the end of the term, upon their mutual written agreement. In addition, the Company became a preferred provider to GSK and its affiliates of genetic testing services on a fee-for-service basis and, in anticipation of the services to be provided, GSK agreed to make a non-refundable upfront payment.
	The Company recognized revenue of $1,134,366 and $174,597 relating to the GSK agreement for the years ended December 31, 2013 and 2014, respectively.
	Non-Exclusive License Agreement with GSK
	In March 2010, the Company entered into a non-exclusive license agreement with GSK.  Under the agreement, the Company granted GSK a non-exclusive, sublicenseable license to its proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples.  As part of the agreement, the Company received a non-refundable technology access fee in consideration for the transfer of the Company’s technology to GSK. The agreement also contains milestone provisions which allowed the Company to earn up to $1.5 million in further payments from GSK.  The Company earned milestone payments from GSK totaling $1,000,000 for the year ended December 31, 2013. This amount is included in the total revenue from GSK discussed above.
	Master Services Agreement with GlaxoSmithKline Biologicals S.A. (“GSK Bio”)
	On July 26, 2012, the Company entered into a second amended and restated master services agreement with GSK Bio, the vaccine division of GSK. The agreement, which was effective as of May 15, 2012, was amended to extend the term to December 31, 2015 on December 17, 2014. Pursuant to this agreement, as amended, the Company provides testing services for clinical trials and epidemiology studies relating to GSK Bio’s cancer immunotherapies. The Company performs these testing services on a fee-for-service basis as embodied in written task orders. GSK Bio retains the intellectual property rights to inventions, improvements and data resulting from the services performed under the Agreement. The Company retains all intellectual property rights to its testing services, proprietary processes. All intellectual property owned by either party on the date of the Agreement remains the exclusive property of the owning party.
	The Agreement will which expire on December 31, 2015 provided that any outstanding task orders at the time of termination will not automatically terminate (unless otherwise agreed in writing by the parties), and any such task orders will continue for the respective terms specified in such task orders (and the parties shall continue to perform their obligations under such task orders. GSK Bio may terminate the agreement, without cause, upon 90 days’ written notice to the Company. The Company may terminate the agreement, without cause, upon one year’s written notice to GSK Bio. The agreement may also be terminated early if either party enters bankruptcy or similar proceedings or in the event of a material breach. GSK Bio may terminate the agreement immediately if the Company experiences a “change of control,” as defined in the agreement.
	The agreement with GSK Bio also provides for mutual indemnification by the parties and contains customary representations, warranties and covenants, including covenants governing the parties’ use of confidential information and representations regarding adequate insurance coverage or self-insurance.
	The Company recognized revenue of $3,534,619 and $1,287,184 relating to the services performed for GSK Bio for the years ended December 31, 2013 and 2014, respectively.
	Collaboration Agreement with Shanghai BioChip Company, Ltd. (“SBC”)
	On March 5, 2007, the Company entered into a collaboration agreement with SBC pursuant to which SBC provides exclusive pharmacogenomic testing services to the Company’s clients in China.
	Pursuant to the agreement, the Company has granted SBC an exclusive license in China to provide services in China using the Company’s proprietary RNA extraction technologies. Subject to consent from USC, the Company granted SBC an exclusive sublicense to patents licensed from USC for distribution of testing services in China. In turn, SBC performs RNA extraction from formalin-fixed paraffin-embedded (“FFPE”) tissue specimens exclusively for the Company during the term of the agreement.
	This agreement had an initial term of five years, with an automatic renewal for an additional three-year term unless either party gives 90 days’ notice in advance of the renewal date of its intent not to renew. As neither party gave notice of intent not to renew, the agreement has automatically renewed for a successive three year period. Pursuant to the agreement, SBC receives a percentage of the gross margin, as defined in the agreement, collected from the Company’s clients in China as compensation for its testing services performed. For the year ended December 31, 2013, and December 31, 2014, testing services totaled $35,027 and $48,948, respectively.

Stock_Option_Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plans	7. Stock Option Plans
	In March 2000, the Company adopted a Stock Option Plan (the “2000 Stock Plan”) as approved by its Board of Directors. Under the 2000 Stock Plan, the Company granted options to acquire up to 1,600,000 shares of common stock. In connection with the adoption of the 2006 Employee, Director and Consultant Stock Plan, as further discussed below, the Company is to grant no additional options under the 2000 Stock Plan. Under the 2000 Stock Plan, there were no options to purchase shares of the Company’s common stock that remained outstanding as of December 31, 2012. Prior to March 2007, the Company also granted options to purchase 16,000 shares of common stock to two consultants which were granted under separate agreements outside of the 2000 Stock Plan.
	On October 26, 2006, the Board of Directors of the Company approved, and on May 1, 2007, reapproved the adoption of the 2006 Employee, Director and Consultant Stock Plan (the “2006 Stock Plan”). The stockholders approved the 2006 Stock Plan on June 1, 2007. The initial number of shares which may be issued from time to time pursuant to the 2006 Stock Plan was 2,160,000 shares of common stock. Also, the 2006 Stock Plan includes the number of shares subject to purchase under options issued under the 2000 Stock Plan, where the options expired on or after October 18, 2006, subject to a maximum of 210,000 additional options.  In addition, on the first day of each fiscal year of the Company during the period beginning in fiscal year 2008 and ending on the second day of fiscal year 2017, the number of shares that may be issued from time to time pursuant to the 2006 Stock Plan is increased by the lesser of (i) 200,000 shares or equivalent, after determination of the effect of any stock split, stock dividend, combination or similar transactions as set forth in the 2006 Stock Plan, (ii) 5% of the number of outstanding shares of common stock of the Company on such date or (iii) an amount determined by the Board of Directors of the Company.  The initial number of shares available for issuance of 2,160,000 increased by 210,000 for options issued under the 2000 Stock Plan expiring after October 2006 and by 200,000 in each year from 2008 through 2014, resulting in the total number of shares that may be issued as of January 1, 2014 to be 3,770,000.  As of December 31, 2014, there were 778,123 options available for grant under the 2006 Stock Plan.
	Employee options vest according to the terms of the specific grant and expire 10 years from the date of grant. Non-employee option grants to date vest typically over a 2 to 3 year period. Under the 2006 Stock Plan, the Company had 2,833,604 options outstanding at a weighted average exercise price of $1.62 at December 31, 2014. There were 1,334,675 non-vested stock options with a weighted average grant date fair value of $0.86 outstanding at December 31, 2014.  As of December 31, 2014, there was $886,906 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Stock Plan.  That cost is expected to be recognized over a weighted-average period of 2.6 years.
	Except for the certain grants of restricted common stock and common stock options containing market conditions as described below, the Company estimated share-based compensation expense for the years ended December 31, 2013 and 2014 using the Black-Scholes model with the following weighted average assumptions:
			Year Ended December 31,
			2013			2014
	Risk free interest rate		0.90-1.77	%		1.78-1.91	%
	Expected dividend yield		—			—
	Expected volatility		102.2-107.4	%		98.4-103.3	%
	Expected term **(in years)		5.0-6.0			5.5-6.0
	Forfeiture rate***		7	%		0% -21	%
	** Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the lack of historical exercises and the standard terms of the employee option grants, including options are granted at-the-money, exercise is conditional only on performing service through the vesting dates, termination of service causes forfeiture of options, employees have a limited number of days to exercise options after termination of service, and options are non-transferable.
	*** Forfeiture range represents 0% for directors and 21% for employees.
	The following table summarizes the stock option activity for the 2000 Stock Plan and the 2006 Stock Plan for the years ended December 31, 2013 and 2014:
						Weighted
						Average			Remaining			Aggregate
			Number of			Exercise			Contractual			Intrinsic
			Shares			Price			Life (Years)			Value
	Outstanding, December 31, 2012			1,749,310		$	2.12			8.32		$	151,919
	Granted			1,115,750			1.33
	Exercised			-18,023			1.33
	Expired			-253,060			2.3
	Forfeited			-305,901			1.39
	Outstanding, December 31, 2013			2,288,076		$	1.83			8.41		$	1,082
	Granted			815,250			0.87
	Exercised			-20,000			1.16
	Expired			-47,923			1.35
	Forfeited			-201,799			1.24
	Outstanding, December 31, 2014			2,833,604			1.62			7.91			-
	Exercisable, December 31, 2014			1,498,929		$	2.07			6.94		$	-
	The weighted-average grant-date fair value of options granted during the years ended December 31, 2013 and 2014 was $1.07 and $0.70, respectively. The aggregate intrinsic value of outstanding options at December 31, 2014 and the options exercised during 2014 were $-0- and $7,605, respectively, which represents options whose exercise price was less than the closing fair market value of the Company’s common stock on December 31, 2014 of $0.32.
	The following table provides additional information in regards to options outstanding as of December 31, 2014:
				Options Outstanding						Options Exercisable
							Weighted Average						Weighted Average
							Remaining						Remaining
				Number of			Contractual			Number of			Contractual
	Exercise Price			Options			Term			Options			Term
	$	0.67 to 0.99			730,771			9.5			68,635			9.5
		1.00 to 1.99			1,597,331			8.1			956,875			7.8
		2.00 to 2.99			288,002			6.6			255,919			6.5
		3.00 to 3.99			71,000			3.6			71,000			3.6
		4.29			11,500			2.6			11,500			2.6
		7			135,000			2.4			135,000			2.4
					2,833,604			7.9			1,498,929			6.9
	Stock-based compensation expense - employees was classified in the results of operations as follows:
			Year Ended December 31,
			2013			2014
	Cost of revenue		$	30,527		$	44,597
	Selling and marketing expense			29,791			36,321
	General and administrative expense			372,158			642,564
	Research and development expense			41,625			52,763
	Totals		$	474,101		$	776,245
	Restricted stock compensation expense – consultants was classified in the results of operations as follows:
			Year Ended December 31,
			2013			2014
	General and administrative expense		$	-		$	86,250
	Thomas Bologna was appointed Chief Executive Officer of the Company on December 21, 2011 and in connection with his appointment, Mr. Bologna was awarded stock options outside of the 2006 Stock Plan. On September 25, 2014, the Company and Mr. Bologna entered into an amendment to Mr. Bologna’s employment agreement which amendment extended the term of Mr. Bologna’s employment agreement to December 31, 2015. Pursuant to the employment agreement between the Company and Mr. Bologna, dated December 21, 2011, and in reliance on NASDAQ Listing Rule 5636(c), the Company granted Mr. Bologna (i) a stock option to purchase 600,000 shares of the Company’s common stock, which vests monthly over 36 months from the date of grant, subject to his continued employment with the Company, (ii) a stock option to purchase 300,000 shares of the Company’s common stock, which vests in two equal installments on the first day of the 18th and 36th calendar months from the date of grant, subject to his continued employment with the Company, or if earlier, the date on which the 30-day trailing average closing price of the Company’s common stock equals or exceeds $1.80, and (iii)  270,000 shares of restricted common stock of the Company, which vest on the date on which the 30-day trailing average closing price of the Company’s common stock equals or exceeds $2.40. The exercise price of the stock options is $1.20 per share, the closing price of the Company’s common stock on the day prior to the date of grant. The expense recognized in connection with these grants was approximately $178,122 and $168,149 for the years ended December 31, 2013 and 2014, respectively, and is included in the above table.
	Since the restricted shares of common stock grant vests upon attainment of a target price for the Company’s common stock and each tranche of the 300,000 share common stock option grant can vest sooner than the stated vesting dates based upon attainment of a target price for the Company’s common stock, these awards are deemed to include market conditions for purposes of determining the valuation and accounting for the awards. Accordingly, the fair value of the restricted shares of common stock grant and each tranche of the 300,000 share common stock option grant that Mr. Bologna received was determined using a Monte-Carlo simulation model to simulate the Company’s stock prices in the future that would trigger or not trigger the market conditions. For these awards containing market conditions, the compensation amount will be attributed over the service date unless vesting occurs sooner due to achieving the market condition.
	The following table summarizes these awards to Mr. Bologna:
								Intrinsic
								Value as of								Remaining
								December 31,						Options		Contractual
	Type		Grant Date		Number of Awards			2014			Exercise Price			Exercisable		Term
Restricted Shares of Common Stock		12/21/11			270,000		$	—		$	1.2			—		7
Options		12/21/11			600,000		$	—		$	1.2			600,000		7
Options		12/21/11			300,000		$	—		$	1.2			300,000		7
During the first quarter of 2012, Mr. Bologna’s stock option award of 300,000 shares met the conditions for vesting in that the 30-day trailing average closing price of the Company’s common stock exceeded $1.80. The Company recognized expense of $129,000 for the vesting of this tranche of options for Mr. Bologna’s stock awards during the quarter ended March 31, 2012.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes
	The components of the income tax provision were as follows:
		Year Ended December 31,
		20123		2014
	Current
	Federal	$	—	$	—
	Foreign		—		—
	State		—		—
	Total		—		—
	Deferred
	Federal		—		—
	Foreign		—		—
	State		—		—
			—		—
	Income tax provision	$	—	$	—
	For financial statement purposes, loss before income tax provision includes the following components:
		Year Ended December 31,
		2013		2014
	Domestic	$	-8,012,906	$	-13,691,729
	Foreign		-7,609		-7,633
		$	-8,020,515	$	-13,699,362
	A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate of 34% to the Company’s effective income tax rate is as follows:
		Year Ended December 31,
		2013		2014
	Income tax benefit based on federal statutory rate	$	-2,729,000	$	-4,658,000
	State income tax benefit, net of federal income tax		-413,000		-70,000
	Change in deferred tax valuation allowance		3,048,000		4,478,000
	Stock-based compensation		75,000		203,000
	Foreign net operating loss		-		—
	Other, net		19,000		47,000
	Income tax provision	$	—	$	—
	The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and deferred tax liabilities are presented below:
		December 31,		December 31,
		2013		2014
	Deferred tax assets:
	Domestic net operating loss carryforwards	$	15,627,000	$	20,598,000
	Foreign net operating loss carryforwards		800,000		802,000
	Deferred revenue		-		—
	Federal and state tax credit		297,000		297,000
	Stock-based compensation		682,000		803,000
	Capitalized costs		1,232,000		1,164,000
	Other, net		2,129,000		1,581,000
	Total gross deferred tax assets		20,767,000		25,245,000
	Less valuation allowance on deferred tax assets		-20,767,000		-25,245,000
	Net deferred taxes		—		—
	Deferred tax liabilities:
	Plant and equipment, principally accelerated depreciation		—		—
	Total deferred tax liabilities		—		—
	Net deferred taxes	$	—	$	—
	Deferred income taxes result from temporary differences between income tax and financial reporting computed at the effective income tax rate. The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. Management periodically evaluates the recoverability of the deferred tax assets. At such time it is determined that it is more likely than not that deferred tax assets are realizable, the valuation allowance will be reduced.
	The Company files U.S. federal, U.S. state, and foreign tax returns. The Company’s major tax jurisdictions are U.S. federal and the State of California and are subject to tax examinations for the open years from 2003  through 2013.
	As of December 31, 2014, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $54 million and $41 million, respectively. If not utilized, the federal net operating loss and tax credit carryforwards expire beginning in 2021. The state net operating loss carryforward expires beginning in 2015. Section 382 of the Internal Revenue Code contains rules that limit the ability of a company that undergoes an ownership change, which is generally a change in ownership of more than 50.0 percent of its stock over a three-year period, to utilize its net operating loss carryforwards. The Company has had numerous transactions in its common stock, and these transactions may have resulted in a change in ownership that limits the utilization of net operating loss carryforwards. The Company has not evaluated the impact of Section 382, if any, on its ability to utilize its net operating loss carry forwards in future years.
	As of December 31, 2014, the Company had U.K. net operating loss carryforwards totaling approximately $3.0 million that may be carried forward indefinitely. A full valuation allowance has been provided against this asset.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Information	9. Segment Information
	The Company operates in a single reporting segment, with operating facilities in the United States.
	The following enterprise wide disclosure was prepared on a basis consistent with the preparation of the financial statements. The following tables contain certain financial information by geographic area:
		Year Ended December 31,
		2013		2014
	Revenue: (Customer geographic location)
	United States	$	15,219,155	$	15,335,888
	Europe		3,556,354		1,322,669
	Other International		1,028,850		61,770
		$	19,801,359	$	16,720,327
		December 31,		December 31,
		2013		2014
	Long-lived assets:
	United States	$	2,681,666	$	2,037,554
		$	2,681,666	$	2,037,554

Offerings_of_Common_Stock

Offerings of Common Stock	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Offerings of Common Stock	10. Offerings of Common Stock
	August 2013 Issuance of Registered Shares of Common Stock of the Company as Part of the Acquisition of the Pathwork Diagnostics, Inc. Assets
	On August 23, 2013, the Company entered into an asset purchase agreement (the “Pathwork Purchase Agreement”) with Pathwork (assignment for the benefit of creditors), LLC (“Seller”), pursuant to which the Company acquired substantially all of the assets of Pathwork Diagnostics, Inc. (“Pathwork”), which had previously assigned all of its assets to Seller for the benefit of its creditors pursuant to a General Assignment, dated as of April 2, 2013.  Pursuant to the Pathwork Purchase Agreement, the Company acquired the Pathwork assets for the following consideration: (i) an aggregate of 500,000 newly-issued registered shares of the Company’s common stock valued at $1.96 per share, or $980,000, issued to two senior secured creditors of Pathwork which were designated by Seller in the Pathwork Purchase Agreement and (ii) a cash payment of $200,000 to Seller.
	September 2013 Registered Direct Offering
	On September 20, 2013, the Company entered into a definitive agreement with certain institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at a price of $2.05 per share (the "September 2013 Offering"). The September 2013 Offering was completed on September 25, 2013. Gross proceeds of the September 2013 Offering were $1,912,250. Net proceeds, after deducting the placement agent fee and the September 2013 Offering costs, were approximately $1.7 million.
	December 2013 Underwritten Public Offering
	On December 13, 2013, the Company entered into an underwriting agreement with National Securities Corporation (the "Underwriter"), pursuant to which the Underwriter agreed to purchase 4,464,443 shares of the Company's common stock (the "Shares") at the public offering price of $1.20 per share less an underwriting discount of 5%. The Shares were offered and sold by the Company pursuant to an effective registration statement on Form S-3 (File No. 333-171266) filed by the Company with the Securities and Exchange Commission on December 17, 2010, as amended, as supplemented by the prospectus supplement dated December 13, 2013 relating to the offering and the accompanying prospectus (the "December 2013 Offering"). The December 2013 Offering was completed on December 13, 2013. Gross proceeds of the December 2013 Offering were $5,357,332. Net proceeds, after deducting the placement agent fee and the December 2013 Offering costs, were approximately $4.8 million.
	July 2014 and February 2015 Issuance of Warrants in Connection with the SWK Credit Facility
	On July 30, 2014 (the “Closing Date”), the Company entered into a credit agreement (the “SWK Credit Agreement”) with SWK Funding LLC, as the administrative agent (the “Agent” or “SWK”), and the lenders (including SWK) party thereto from time to time (the “Lenders”). The SWK Credit Agreement provides for a multi-draw term loan to the Company (the “Loan”) up to a maximum principal amount of $12,000,000 (the “Loan Commitment Amount”). On the Closing Date, the Lenders advanced the Company an amount equal to $8,500,000 which is due and payable on July 30, 2020 (the “Term Loan Maturity Date”) or such earlier date on which the Loan Commitment Amount is terminated pursuant to the terms of the SWK Credit Agreement. On February 3, 2015 (the “Amendment Closing Date”), the Company and SWK entered into a first amendment (the “Amendment”) to the SWK Credit Agreement.  Pursuant to the Amendment, the Company drew an additional $1,500,000 of the Loan Commitment Amount increasing the total amount advanced to the Company under the SWK Credit Agreement to $10,000,000.
	On the Closing Date, the Company issued to the Agent a warrant (the “Initial Warrant”) to purchase up to 681,090 shares of the Company's common stock. The Initial Warrant was exercisable, in whole or in part, from the date of issuance until and including July 30, 2020 at an exercise price of $0.936 per share, and was subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like. The relative fair value of the Initial Warrant was $377,140, or approximately $0.55 per covered share, using a Black-Scholes pricing model with the following assumptions: 2.01% risk free rate, 0% dividend, 101.5% volatility, and six-year expected life. The value of the warrant was recorded on the balance sheet included in additional paid-in capital. On September 9, 2014, the Agent assigned a portion of the Initial Warrant consisting of the right to purchase 200,321 shares of common stock to SG (the “SG Initial Warrant”). On January 30, 2015, SG assigned the SG Initial Warrant back to the Agent and on the Amendment Closing Date, the Company replaced the Initial Warrant to purchase the total 681,090 shares of the Company’s common stock with a new warrant with an adjusted exercise price (the “Replacement Warrant”).  The Replacement Warrant is exercisable up to and including July 30, 2020 at an exercise price of $0.39 per share.  The Agent may exercise the Replacement Warrant on a cashless basis at any time.  In the event the Agent exercises the Replacement Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the Replacement Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	In addition, on the Amendment Closing Date, the Company issued the Agent a new warrant (the “First Amendment Warrant”) to purchase 576,923 shares of Common Stock.  The First Amendment Warrant is exercisable up to and including February 3, 2021 at an exercise price of $0.39 per share, subject to adjustment.  The Agent may exercise the First Amendment Warrant on a cashless basis at any time.  In the event the Agent exercises the First Amendment Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the First Amendment Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	Common stock classified outside of stockholders’ equity (deficit)
	February 2012 Private Placement
	On February 2, 2012, the Company entered into purchase agreements with various investors (collectively, the “February Investors”) for the private placement of an aggregate of 5,257,267 newly-issued shares of the Company’s common stock (the “February Shares”) at a purchase price of $1.50 per share (the “February 2012 Private Placement”).
	In connection with the February 2012 Private Placement, the Company also entered into registration rights agreements, each dated February 2, 2012, pursuant to which the Company agreed to file, within 90 days of the closing, a registration statement with the SEC to register the February Shares for resale, which registration statement is required to become effective within 180 days following the closing. The Company also granted the February Investors certain “piggyback” registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more shareholders until the earlier of the sale of all of the February Shares or the February Shares becoming eligible for sale under Rule 144(b)(1) without restriction.
	These registration rights agreements do not provide an explicitly stated or defined penalty due upon a breach.  Because (i) the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements and (ii) complying with all filing requirements under the Exchange Act as described above is not solely within the Company’s control, the Company was required to present the investment in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities.
	As of March 31, 2013, the Company has removed the restrictions on all of the February Shares and reclassified all of the February Shares to common stock from common stock classified outside of equity (deficit).
	September 2012 Private Placement
	On September 13, 2012, the Company entered into a purchase agreement (the “Purchase Agreement”) with Glaxo Group Limited, an affiliate of GSK (the “GSK Investor”) and two existing investors, Swiftcurrent Partners, L.P. and Swiftcurrent Offshore, Ltd. (collectively with the GSK Investor, the “September Investors”) for the private placement of an aggregate of 8,000,000 newly-issued shares of the Company’s common stock (the “September Shares”) at a purchase price of $1.10 per share (the “September 2012 Private Placement”).
	Pursuant to the Purchase Agreement, for so long as the GSK Investor or its affiliates own at least 50% of the September Shares it purchased pursuant to the Purchase Agreement, the GSK Investor has the right to designate one non-voting board observer (the "Board Observer"). The Board Observer, if appointed, has the right to attend all meetings of the Board of Directors of the Company and to receive all board meeting materials, subject to certain restrictions set forth in the Purchase Agreement. As of the date hereof, the GSK Investor has not exercised its right to designate the Board Observer.
	In connection with the September 2012 Private Placement, the Company also entered into a registration rights agreement, dated September 13, 2012 (the “September Registration Rights Agreement”), pursuant to which the Company agreed to file, within 45 days of the closing, a registration statement with the SEC to register the September Shares for resale, which registration statement is required to become effective within 180 days following the closing. The Company also granted the September Investors certain “piggyback” registration rights, which are triggered if the Company proposes to file a registration statement for its own account or the account of one or more stockholders until the earlier of the sale of all of the September Shares or the September Shares becoming eligible for sale under Rule 144(b)(1) without restriction.
	The September Registration Rights Agreement does not provide an explicitly stated or defined penalty due upon a breach.  Because the potential penalty for any breach of these registration rights agreement is not explicitly stated or defined, which prohibits the Company from applying the guidance of ASC 825-20-15, Registration Payment Arrangements , the Company was required to present the investment in the Company’s common stock as common stock outside of stockholders’ equity in the accompanying consolidated balance sheet under ASC 480-10-S99-3, Classification and Measurement of Redeemable Securities .
	As of December 31, 2012, the Company had removed the restriction on 3,000,000 of the 8,000,000 September Shares and reclassified the shares to common stock from common stock classified outside of stockholders’ equity (deficit). As of June 30, 2014, the restriction was eligible for removal from the remaining 5,000,000 September Shares and therefore, the Company reclassified the shares to common stock from common stock classified outside of stockholders’ equity (deficit). Therefore, as of December 31, 2013 and 2014, a total of $5,500,000 and $-0- of common stock was classified outside of stockholders’ equity (deficit) related to the September Shares.
	Activity in common stock classified outside of stockholders’ equity (deficit) was as follows:
		Number of	Amount
		Shares
	Balance, January 1, 2013	9,561,847	$	11,775,724
	Issuance of common stock classified outside of stockholders’ equity (deficit)	—		—
	Reclassification to stockholders’ equity (deficit)	-4,561,847		-6,275,724
	Balance, December 31, 2013	5,000,000	$	5,500,000
	Issuance of common stock classified outside of stockholders’ equity (deficit)	—		—
	Reclassification to stockholders’ equity (deficit)	-5,000,000		-5,500,000
	Balance, December 31, 2014	—	$	—

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair Value Measurements
	ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. ASC 820 establishes a three-level valuation hierarchy of valuation techniques that is based on observable and unobservable inputs. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The first two inputs are considered observable and the last unobservable, that may be used to measure fair value and include the following:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	As of December 31, 2013 and 2014, the Company did not hold any assets or liabilities that are required to be measured at fair value on a recurring basis.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events
	SWK Credit Agreement Amendment
	On February 3, 2015 (the “Amendment Closing Date”), the Company entered into a first amendment (the “Amendment”) to that certain credit agreement (the “Credit Agreement”), dated July 30, 2014, with SWK Funding LLC, as the agent (the “Agent”), and the lenders (including SWK Funding LLC) party thereto from time to time (the “Lenders”).  Pursuant to the Amendment, the Company drew an additional $1,500,000 of the maximum $12,000,000 term loan commitment amount (the “Loan Commitment Amount”) increasing the total amount advanced to the Company under the Credit Agreement to $10,000,000. The maturity date for the term loan remains July 30, 2020 (the “Term Loan Maturity Date”) or such earlier date on which the Loan Commitment Amount is terminated pursuant to the terms of the Credit Agreement.
	On the Amendment Closing Date, the Company replaced the warrant to purchase 681,090 shares of the Company's common stock at an exercise price of $0.936 that was initially issued to the Agent on July 30, 2014 (the “Initial Warrant”), with an adjusted exercise price (the “Replacement Warrant”).  The Replacement Warrant is exercisable up to and including July 30, 2020 at an exercise price of $0.39 per share.   The Agent may exercise the Replacement Warrant on a cashless basis at any time.  In the event the Agent exercises the Replacement Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the Replacement Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	In addition, on the Amendment Closing Date, the Company issued the Agent a warrant (the “First Amendment Warrant”) to purchase 576,923 shares of Common Stock.  The First Amendment Warrant is exercisable up to and including February 3, 2021 at an exercise price of $0.39 per share, subject to adjustment.  The Agent may exercise the First Amendment Warrant on a cashless basis at any time.  In the event the Agent exercises the First Amendment Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the First Amendment Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	The remaining $2,000,000 of the Loan Commitment Amount (the “Subsequent Term Loan”) may be advanced to the Company upon written request to the Agent during the period beginning on the Amendment Closing Date and ending February 28, 2016 provided that (i) no default or event of default has occurred or is continuing under the Credit Agreement, (ii) the aggregate revenue recognized by the Company and any of its subsidiaries during any period of four (4) consecutive fiscal quarters ending prior to December 31, 2015, exceeds a certain dollar amount threshold and (iii) the Agent has received an executed warrant (the “Subsequent Term Loan Warrant”) to purchase a number of shares of Common Stock equal to the number obtained when the amount of the Subsequent Term Loan is multiplied by 15% and the product is divided by the exercise price of such warrant.  The exercise price of the Subsequent Term Loan Warrant will be equal to the lower of (a) the average closing price of the Common Stock on the previous 5 trading days before the closing date of the Subsequent Term Loan, or (b) the closing price of the Common Stock on the last trading day prior to such Subsequent Term Loan’s closing date.  The Subsequent Term Loan Warrant will be exercisable for a period of six years from the closing date of the Subsequent Term Loan, subject to adjustment.  Upon issuance, the Agent may exercise the Subsequent Term Loan Warrant on a cashless basis at any time.  In the event the Lenders exercise the Subsequent Term Loan Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the Subsequent Term Loan Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	On January 30, 2015, SG-Financial, LLC (“SG”) assigned to SWK all of the interests under the SWK Credit Agreement that was assigned to SG by SWK, as the initial Lender, on September 9, 2014 including $2,500,000 of the $8,500,000 Closing Date initial advance to the Company and $1,029,412 of the remaining Loan Commitment Amount. In addition, on the same date, SG assigned to SWK the portion of the Initial Warrant consisting of the right to purchase 200,321 shares of common stock of the Company that was assigned to SG by SWK on September 9, 2014. As such as of January 30, 2015, SWK is the sole Lender under the SWK Credit Agreement and held the entire Initial Warrant which was replaced by the Replacement Warrant on February 3, 2015.
	Nasdaq Delisting Extension Update
	On December 19, 2014, the Company received a delisting determination letter from Nasdaq due to the Company not regaining compliance with The Nasdaq Capital Market minimum bid price of $1.00 requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) within 180 days or by December 17, 2014. The delisting determination letter also stated that the Company is not eligible for an additional 180-day extension to regain compliance with the minimum bid price rule because the Company does not meet the minimum $2,500,000 in stockholders’ equity standard for continued listing under Nasdaq Listing Rule 5550(b)(1).
	Pursuant to the determination letter, the Company requested an appeal of this determination and appeared before a Nasdaq Hearing Panel (the “Panel”) on February 5, 2015 and was granted its request for continued listing on the Nasdaq Stock Market, subject to certain conditions, on February 17, 2015. If the Company fails to meet the terms of the Panel’s decision by June 19, 2015, the Panel will issue a final delist determination and the Company will be suspended from trading on the Nasdaq Stock Market.
	The Company believes that it is in the process of complying with the conditions set by the Panel for continued suspension of delisting. However, there can be no assurance that the Company will be able to timely meet all of the conditions and continue to be listed on Nasdaq. If the Company’s common stock ceases to be listed for trading on the Nasdaq Capital Market, the Company expects that its common stock would be traded on the OTC Markets on or about the same day.

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II
	RESPONSE GENETICS, INC.
	VALUATION AND QUALIFYING ACCOUNTS
		Balance at
		Beginning of		Additions  Charged to				Balance at End
		Period		Costs and Expenses		Deductions		of Period
	Allowance for Doubtful Accounts
	Year ended December 31, 2014	$	2,404,659	$	5,842,212	$	-6,175,165	$	2,071,706
	Year ended December 31, 2013	$	991,990	$	3,165,918	$	-1,753,249	$	2,404,659

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Basis of Consolidation	Basis of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Response Genetics, Ltd., a Scottish corporation (the “Subsidiary”), which was incorporated in November 2006. The Subsidiary had no employees or active operations during 2013 and 2014. All significant intercompany transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value due to the short-term nature and liquidity of these instruments. The Company’s cash equivalents are comprised of cash on hand, deposits in banks and money market investments.
Accounts Receivable	Accounts Receivable
	Pharmaceutical Accounts Receivable
	The Company invoices its clients as specimens are processed and any other contractual obligations are met. The Company’s contracts with clients typically require payment within 45 days of the date of invoice. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its clients to make required payments. The Company specifically analyzes accounts receivable and historical bad debts, client credit, current economic trends and changes in client payment trends when evaluating the adequacy of the allowance for doubtful accounts. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered. To date, the Company’s clients have primarily been large pharmaceutical companies. As a result, bad debts from clinical accounts receivable to date have been minimal. Pharmaceutical company accounts receivable as of December 31, 2013 and 2014 were $1,892,384 and $1,037,834 respectively.  There were no allowances for doubtful accounts recorded against these pharmaceutical accounts receivable at December 31, 2013 and 2014.
	ResponseDX® Accounts Receivable
	ResponseDX® accounts receivable are recorded from two primary payors: Medicare and third party/private payors (“Private Payors”).  ResponseDX® accounts receivable are recorded at established billing rates less an estimated billing adjustment, based on reporting models utilizing historical cash collection percentages and updated for current effective reimbursement factors.  Management performs ongoing valuations of accounts receivable balances based on management’s evaluation of historical collection experience and industry trends.  Based on the historical experience for the Company’s  accounts, management has determined, based on a detailed analysis, that accounts receivable associated with certain billings are unlikely to be collected.  Therefore, the Company has recorded an allowance for doubtful accounts of $2,404,659 and $2,071,706 as of December 31, 2013 and 2014. The Company’s bad debt expense for the years ended December 31, 2013 and 2014 was $3,165,918 and $5,842,212, respectively.
	ResponseDX® accounts receivable consisted of the following:
		December 31,		December 31,
		2013		2014
	Net Medicare receivable	$	2,422,611	$	2,814,989
	Net Private Payor receivable		4,315,587		6,029,300
			6,738,198		8,844,289
	Allowance for doubtful accounts		-2,404,659		-2,071,706
		$	4,333,539	$	6,772,583
	As more fully discussed in Note 3 Property and Equipment and Intangible Assets, the Company acquired accounts receivable in August 2013 that had a valuation of $257,000. All of these receivables were collected by December 31, 2013.
	As part of its process for evaluating the collectability of aged accounts receivable management identified delays in the Medicare administrative law appeal process for aged accounts receivable that would extend the process significantly (up to two years). Accordingly, management considered this factor in estimating the allowance for doubtful accounts and concluded that an additional allowance of approximately $690,000 was necessary as of December 31, 2013 to reserve for the balance of Medicare accounts receivable as of December 31, 2013 that were going to age greater than one year shortly after December 31, 2013. At December 31, 2014 all Medicare accounts receivable outstanding greater than one year have been reserved 100%.
Property and Equipment	Property and Equipment and Intangible Assets
	Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows:
	Laboratory equipment	5 to 7 years
	Furniture and equipment	5 to 7 years
	Purchased and internally-developed software	3 to 5 years
	Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term
	Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. The Company has capitalized costs related to the development of database software (see Note 3). The portion of this database placed into service is amortized in accordance with ASC 350-40, Internal-Use Software. The amortization period is five years using the straight-line method.
Revenue Recognition	Revenue Recognition
	Pharmaceutical Revenue
	Revenues that are derived from testing services provided to pharmaceutical companies are recognized on a contract specific basis pursuant to the terms of the related agreements. Revenue is recognized in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
	Revenues are recorded on an accrual basis as the contractual obligations are completed and as a set of assays is processed through the Company’s laboratory under a specified contractual protocol and are recorded on the date the tests are resulted. Certain contracts have minimum assay requirements that, if not met, result in payments that are due upon the completion of the designated period. In these cases, revenues are recognized when the end of the specified contract period is reached.
	On occasion, the Company may enter into a contract that requires the client to provide an advance payment for specimens that will be processed at a later date. In these cases, the Company records this advance as deferred revenue and recognizes the revenue as the specimens are processed or at the end of the contract period, as appropriate. There was no deferred revenue at December 31, 2013 or December 31, 2014.
	In March 2010, the Company entered into a non-exclusive license agreement with GlaxoSmithKline, LLC, which called for certain milestone payments to be made to the Company when certain events specified in the agreement occur, specifically GlaxoSmithKline, LLC submitting an application to use the license to the FDA, the FDA approving the application, and issuance of certain patent applications to the Company. The Company has no further obligations related to these events and therefore has recorded the milestone payments that were due under the agreement into revenue at the time the event occurred. Milestone payments received in 2013 and 2014 were $1,000,000 and $-0-, respectively.
	The Company recorded net revenue from pharmaceutical clients of $7,789,985 and $2,124,130 for the years ended December 31, 2013 and 2014, respectively.
	ResponseDX® Revenue
	The Company recognizes revenues when (a) the price is fixed or determinable, (b) persuasive evidence of an arrangement exists, (c) the service is performed and (d) collectability of the resulting receivable is reasonably assured. The Company’s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent and revenues are recognized once the diagnostic services have been performed, and the results have been delivered to the ordering physician.
	Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, commercial insurance plans and Medicare programs. Billings for services under third-party payer programs are included in revenue net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated payment amounts.  Significant judgment is inherent in the selection of assumptions and the interpretation of historical experience as well as the identification of external and internal factors affecting the determination of these reserves for Medicare, private health insurance companies, healthcare institutions, and patients. The Company reports revenues from contracted payers, including Medicare, certain insurance companies and certain healthcare institutions, based on the contractual rate, or in the case of Medicare, published fee schedules. The Company reports revenues from non-contracted payers, including certain insurance companies and individuals, based on the amount expected to be collected. The difference between the amount billed and the amount estimated to be collected from non-contracted payers is recorded as a contractual allowance to arrive at the reported net revenues. The expected revenues from non-contracted payers are based on the historical collection experience of each payer or payer group, as appropriate.The assumptions used to determine these contractual allowances are reasonable considering known facts and circumstances. If actual future payments are less than the estimates the Company made at the time of recognizing revenue, the consolidated financial position, results of operations and cash flows may be negatively impacted. If actual future payments are materially different from the contracted amounts or estimates, the difference is accounted for as a change in estimate in the period in which they become known. Adjustments to the estimated payment amounts based on final settlement are recorded upon settlement as an adjustment to revenue. In 2014 and 2013, approximately 38% and 33.5%, respectively, of the Company's revenues were derived directly from the Medicare program. The Company’s Medicare provider number allows it to invoice and collect from Medicare. The Company’s invoicing to Medicare is primarily based on amounts allowed by Medicare for the service provided as defined by Common Procedural Terminology (“CPT”).   Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation.
	The following details ResponseDX® revenue for the years ended December 31, 2013 and 2014:
		Year Ended December 31,
		2013		2014
	Net Medicare revenue	$	4,521,732	$	4,886,507
	Net Private Payor revenue		7,489,642		9,709,690
	Net ResponseDX® revenue	$	12,011,374	$	14,596,197
	The Company recognizes revenue for services covered by Medicare based on the Medicare fee schedule. The Company’s fees for January to October 2013 were based the 2013 initial annual Medicare fee schedule. From October 2013 through December 2013, the fees were based on Centers for Medicare and Medicaid Services (“CMS”) updated payment rates for some, but not all of the Common Procedural Terminology (“CPT”) codes used by the Company. For the remaining CPTs not covered by the CMS update, the Company used the Medicare fees provided by the local Medicare Administrative Contractor proposed reimbursement rates. For 2014, the Company’s Medicare fees were based on the Centers for Medicare and Medicaid Services (“CMS”) proposed “Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule, Clinical Laboratory Fee Schedule & Other Revisions to Part B for CY 2014” released in July 2013.
	The Company updates its estimates of Medicare fees based on current information from CMS. The nature of the testing services the Company provides, the evidence the Company gathers to establish the creditworthiness of its payors and the delivery method of its services have not changed from prior periods, and therefore these assumption remain appropriate.
Cost of Revenue	Cost of Revenue
	Cost of revenue represents the cost of materials, direct labor, royalties, costs associated with processing tissue specimens including pathological review, staining, microdissection, paraffin extraction, reverse transcription polymerase chain reaction, fluorescence in situ hybridization (“FISH”), quality control analyses, license fees and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.
License Fees	License Fees
	The Company has licensed technology for the extraction of ribonucleic acid (“RNA”) from formalin-fixed, paraffin-embedded tumor specimens from the University of Southern California (“USC”). Under the terms of the license agreement, the Company is required to pay royalties to USC calculated as a fixed percentage of net sales price as defined in the agreement that the Company generates by using this technology. Total license fees expensed in cost of revenue under the license agreement with USC were $305,616 for the year ended December 31, 2013 and $42,289 for the year ended December 31, 2014. In addition, in the year ended December 31, 2014, the Company recorded credits to the royalty expense of $240,077 in each of the third and fourth quarters, representing, in the aggregate, a one-time $480,154 adjustment for the period over-accruals resulting from a change in the estimate of royalty expense. The net credit of $437,865 is included in our cost of revenue.  The Company also maintains a non-exclusive license to use certain patents related to the polymerase chain reaction (“PCR”) of Roche Molecular Systems, Inc. (“Roche”). The Company pays Roche a royalty fee based on revenue that the Company generates through use of this technology. The Company accrues for such royalties at the time revenue is recognized. Royalties expensed in cost of revenue under the Roche agreement totaled $280,325 and $211,932 for the years ended December 31, 2013 and 2014, respectively. Such royalties are included in cost of revenues in the accompanying statements of operations.
	Royalty expense is based on a fixed percentage of net sales price as defined in the agreement of specific tests pursuant to terms set forth in the agreements with USC and Roche. The amount due is calculated based on the revenue the Company recognizes using the respective licensed technology. The royalty expense recognized, like the associated revenue, depends on the timing of the specimens submitted by the Company’s clients for testing.
	Additionally, the Company periodically analyzes the technical procedures performed in its test offerings to assess which activities utilize licensed technologies and to calculate royalties for use of the licensed technology. The most recent analyses indicate that the Company could owe less than the amounts that have been accrued for royalties payable and based on the Company’s discussions with USC, the Company has taken a credit for its USC royalties over-accrual. Roche is still reviewing the Company’s updated royalty calculations. It is possible that based on Roche’s review and the Company’s discussions with Roche, the Company may further adjust its Roche royalty accrual.
Research and Development	Research and Development
	The Company expenses costs associated with research and development activities as incurred. Research and development costs are expensed as incurred and classified as research and development costs. Research and development costs include employee costs (salaries, payroll taxes, benefits, and travel), equipment depreciation and maintenance, laboratory supplies, primers and probes, reagents, patent costs and occupancy costs.
Line of Credit	Line of Credit
	On July 14, 2011, the Company entered into a line of credit agreement with Silicon Valley Bank (the “Bank”). The agreement has been amended most recently on July 30, 2014, as discussed below. The line of credit is collateralized by all of the Company’s assets including its pharmaceutical, Private Payor and Medicare receivables. The amended maximum amount that can be borrowed from the credit line is $2,000,000. As of December 31, 2013 and 2014, the amount the Company can draw from the loan was $1,000,000 and $500,000, respectively, calculated as the lesser of (i) the Company’s calculated borrowing base, which was 80% of certain of the Company’s accounts receivable, or (ii) the amount available under the credit line. As of December 31, 2013, the interest fees associated with this line of credit were set at the prime rate plus 1%.  Effective with the July 30, 2014 amendment to this credit agreement, the interest rate was set at prime plus 2.25%. During 2013 and the first half of 2014, the rate charged to the Company was 5%. For the latter half of 2014 the rate charged to the Company was 5.5%. As needed from time to time, the Company may draw on this line for use for general corporate purposes. As of December 31, 2013 and December 31, 2014, the Company has drawn $1,000,000 and $1,500,000 against the line of credit. The line of credit is subject to various financial covenants. In 2013 the Company was in violation of certain of these covenants and, pursuant to an amendment on March 7, 2013, the Bank waived the Company's existing breach of financial covenants under the credit agreement and the parties restructured the line of credit to provide that, among other things: (i) the revolving line of credit's maturity date was extended to March 7, 2015, (ii) the fee for the unused portion of the revolving line of credit was reduced from 0.375% to 0.250% per annum of the average unused portion of the revolving line of credit, (iii) the Company must continue to meet certain reporting requirements including providing financial statements and a certificate of compliance with the terms and conditions of the credit agreement by an authorized officer to the Bank within 45 days of the last day of each calendar quarter, provided that if the Company has less than $4,000,000 in its account at the Bank at any time during such calendar quarter, the Company must provide the financial statements and the certificate of compliance within 30 days of the end of such calendar quarter and provide a monthly report on revenues realized from private payors, (iv) the financial covenants were amended and restated to require the Company to maintain a ratio of quick assets to current liabilities of 1:50 to 1:00 and meet certain specified minimum adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) requirements as defined in the amendment and measured on a monthly basis and (v) the Bank is granted certain additional inspection of books, records and collateral rights.
	On July 30, 2014, the Bank waived several additional covenant violations and amended the credit agreement to provide, among other things: (i) an increase in the interest rate to prime plus 2.25%; (ii) the addition of an “Early Termination Fee” of $40,000; (iii) an adjusted quick ratio of at least 1.25 to 1.00; (iv) permission for the Company to receive up to $12,000,000 from a third party term loan; (v) a requirement that the Company maintain quarterly rolling twelve-month net revenue balances beginning December 31, 2014; and (vi) a requirement that the Company maintain quarterly minimum liquidity of $1,000,000 and (vii) an extension of the revolving line of credit's maturity date to July 25, 2016. At December 31, 2014 the Company was in compliance with these covenants.
	As of December 31, 2013 and 2014, the line of credit under the credit agreement was classified as a non-current liability of the Company on the accompanying balance sheet as the line of credit had a maturity date of greater than one year.
	From time to time, the Company’s calculated borrowing base under its Bank line of credit may decrease to a level where the Company is in an over-advance position in which case the Company will be required to repay any outstanding amounts greater than the calculated borrowing base for such covered period back to the Bank immediately. The Company will be able to draw down on the credit line again with respect to such paid back amount once the Company is in compliance with the borrowing base requirement.
SWK Term Loan	SWK Term Loan
	On July 30, 2014 (the “Closing Date”), the Company entered into a credit agreement (the “SWK Credit Agreement”) with SWK Funding LLC, as the administrative agent (the “Agent” or “SWK”), and the lenders (including SWK) party thereto from time to time (the “Lenders”). The SWK Credit Agreement provides for a multi-draw term loan to the Company (the “Loan”) up to a maximum principal amount of $12,000,000 (the “Loan Commitment Amount”). On the Closing Date, the Lenders advanced the Company an amount equal to $8,500,000 which is due and payable on July 30, 2020 (the “Term Loan Maturity Date”) or such earlier date on which the Loan Commitment Amount is terminated pursuant to the terms of the SWK Credit Agreement. On February 3, 2015 (the “Amendment Closing Date”), the Company and SWK entered into a first amendment (the “Amendment”) to the SWK Credit Agreement.  Pursuant to the Amendment, the Company drew an additional $1,500,000 of the Loan Commitment Amount increasing the total amount advanced to the Company under the SWK Credit Agreement to $10,000,000.
	The Loan bears interest at a rate equal to the LIBOR Rate (as defined in the SWK Credit Agreement) plus an applicable margin of 12.5% per annum, subject to a one percent (1.0%) LIBOR floor. Interest on the Loan is due and payable in arrears (i) on the forty-fifth (45th) day following the last calendar day of each of the months of September, December, March, and June, commencing on November 15, 2014, (ii) upon a prepayment of the Loan and (iii) on the Term Loan Maturity Date. At December 31, 2014, the interest rate charged to the Company was 13.5%. Upon the earlier of (a) the Term Loan Maturity Date or (b) full repayment of the Loan, the Company is also required to pay an exit fee.
	On September 9, 2014, SWK, in its capacity as the initial Lender, assigned part of its interests under the SWK Credit Agreement to SG-Financial, LLC (“SG”). Pursuant to the assignment, SG was assigned $2,500,000 of the $8,500,000 Closing Date initial advance to the Company and $1,029,412 of the subsequent term loan commitment. Pursuant to the assignment, as of the effective date of the assignment, SG became a party to the SWK Credit Agreement as a Lender. On January 30, 2015, SG assigned all of its interests under the SWK Credit Agreement to SWK. As such, as of January 30, 2015, SWK is the sole Lender under the SWK Credit Agreement.
	On the Closing Date, the Company issued to the Agent a warrant (the “Initial Warrant”) to purchase up to 681,090 shares of the Company's common stock. The Initial Warrant was exercisable, in whole or in part, from the date of issuance until and including July 30, 2020 at an exercise price of $0.936 per share, and was subject to customary adjustments for stock splits, stock dividends, recapitalization and the like. The relative fair value of the Initial Warrant was $377,140, or approximately $0.55 per covered share, using a Black-Scholes pricing model with the following assumptions: 2.01% risk free rate, 0% dividend, 101.5% volatility, and six-year expected life. The value of the warrant was recorded on the balance sheet included in additional paid-in capital. On September 9, 2014, the Agent assigned a portion of the Initial Warrant consisting of the right to purchase 200,321 shares of common stock to SG (the “SG Initial Warrant”). On January 30, 2015, SG assigned the SG Initial Warrant back to the Agent and on the Amendment Closing Date, the Company replaced the Initial Warrant to purchase the total 681,090 shares of the Company’s common stock with a new warrant with an adjusted exercise price (the “Replacement Warrant”).   The Replacement Warrant is exercisable up to and including July 30, 2020 at an exercise price of $0.39 per share.  The Agent may exercise the Replacement Warrant on a cashless basis at any time.  In the event the Agent exercises the Replacement Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the Replacement Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	In addition, on the Amendment Closing Date, the Company issued the Agent a new warrant (the “First Amendment Warrant”) to purchase 576,923 shares of Common Stock.  The First Amendment Warrant is exercisable up to and including February 3, 2021 at an exercise price of $0.39 per share, subject to adjustment.  The Agent may exercise the First Amendment Warrant on a cashless basis at any time.  In the event the Agent exercises the First Amendment Warrant on a cashless basis, the Company will not receive any proceeds.  The exercise price of the First Amendment Warrant is subject to customary adjustments for stock splits, stock dividends, recapitalizations and the like.
	For accounting purposes, the proceeds received pursuant to the SWK Credit Agreement were allocated to the liability for debt, a debt issuance discount and additional paid-in capital for the Initial Warrant based upon the relative fair value of the loan and the Initial Warrant. The amounts recorded in the financial statements were $8,500,000 for loan liability, $576,161 for debt issuance discount and $377,140 to additional paid-in capital for the Initial Warrant. Additionally, the Company recorded deferred loan issuance costs of $187,092 for investment banker fees and legal fees incurred to enter into the SWK Credit Agreement. The debt issuance discount and the deferred issuance costs are being amortized to interest expense over the six-year term of the loan.
	The remaining $2,000,000 of the Loan Commitment Amount (the “Subsequent Term Loan”) may be advanced to the Company upon written request to the Agent during the period beginning on the Amendment Closing Date and ending February 28, 2016 provided that (i) no default or event of default has occurred or is continuing under the SWK Credit Agreement, (ii) the aggregate revenue recognized by the Company and any of its subsidiaries during any period of four (4) consecutive fiscal quarters ending prior to December 31, 2015 exceeds a certain dollar amount threshold and (iii) the Agent has received an executed warrant (the “Subsequent Term Loan Warrant”) to purchase a number of shares of common stock equal to the number obtained when the amount of the Subsequent Term Loan is multiplied by 15% and the product is divided by the exercise price of such warrant. The exercise price of the Subsequent Term Loan Warrant will be equal to the lower of (a) the average closing price of the common stock on the previous 5 trading days before the closing date of the Subsequent Term Loan, or (b) the closing price of the common stock on the last trading day prior to such Subsequent Term Loan’s closing date. The Subsequent Term Loan Warrant will be exercisable for a period of six years from the closing date of the Subsequent Term Loan, subject to adjustment. Upon issuance, the Agent may exercise the Subsequent Term Loan Warrant on a cashless basis at any time. In the event the Lender exercises the Subsequent Term Loan Warrant on a cashless basis, the Company will not receive any proceeds. The exercise price of the Subsequent Term Loan Warrant is subject to customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like.
	The Company may prepay the Loan, in whole or in part, upon five business days’ written notice provided that a prepayment premium is paid to the Lenders as set forth in the SWK Credit Agreement. The Company is required to prepay the Loan with any net cash proceeds received from certain types of dispositions of assets described in the SWK Credit Agreement. The Company is also required to make certain revenue-based payments on the Company’s quarterly revenues, applied in the following priority: (i) first, to the payment of all fees, costs, expenses and indemnities due and owing to the Agent under the SWK Credit Agreement, (ii) second, to the payment of all fees, costs, expenses and indemnities due and owing to the Lenders under the SWK Credit Agreement, (iii) third, to the payment of all accrued but unpaid interest until paid in full, (iv) fourth, for each revenue-based payment date after August 2016, to the payment of all principal of the Loan up to an aggregate amount of $750,000 on any such payment date and (v) fifth, all remaining amounts to the Company.
	As of December 31, 2014, the term debt under SWK Credit Agreement was classified as a non-current liability of the Company on the accompanying balance sheet as the repayment terms are based on future revenues that cannot be reasonably estimated and therefore all outstanding amounts are classified as non-current.
	The SWK Credit Agreement contains customary affirmative and negative covenants for credit facilities of its type, including covenants that limit the Company’s ability to pay dividends or redeem outstanding equity interests, incur additional indebtedness, grant additional liens, engage in any other type of business, make investments, merge, consolidate or sell all or substantially all of its assets and enter into transactions with related parties. The SWK Credit Agreement also contains certain financial covenants, including certain minimum aggregate revenue requirements. The Company was in compliance with these covenants at December 31, 2014.
	The SWK Credit Agreement includes customary events of default, including failure to pay principal, interest or fees when due, failure to comply with covenants, default under certain other indebtedness, certain insolvency or bankruptcy events, the occurrence of certain material judgments, the institution of any proceeding by a government agency or a change of control of the Company that it is not otherwise permitted under the SWK Credit Agreement.
Income Taxes	Income Taxes
	Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
	ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of December 31, 2013 and 2014, the Company does not have a liability for unrecognized tax benefits. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision, and the Company includes accrued interest and penalties with the related tax liability in the balance sheet. For the years ended December 31, 2013 and 2014, there were no interest or penalties recorded on the consolidated statement of operations.
Stock-Based Compensation	Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation, Share-Based Payment. Stock-based compensation expense for all stock-based compensation awards granted is based on the grant-date fair value estimated in accordance with the provisions of ASC 718.  The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting period. As further described in Note 7, certain awards granted to Thomas A. Bologna, the Company’s Chairman and Chief Executive Officer, were recognized based on an accelerated vesting basis triggered by market conditions rather than a straight-line basis.
	The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, Equity. Under ASC 505, stock option awards issued to non-employees are measured at fair value using the Black-Scholes option-pricing model and recognized pursuant to a performance model.
Management Estimates	Management Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates in these consolidated financial statements have been made for revenue, allowances for doubtful accounts, impairment of long-lived assets, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
Long-lived Assets	Long-lived Assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates potential impairment by comparing the carrying amount of the asset with the estimated undiscounted future cash flows associated with the use of the asset and its eventual disposition. Should the review indicate that the assets cost is not recoverable, the carrying value of the asset would be reduced to its fair value, which is measured by future discounted cash flows.
Foreign Currency Translation	Foreign Currency Translation
	The financial position and results of operations of the Company’s foreign subsidiary are determined using local currency as the functional currency. Assets and liabilities of these operations are translated at the exchange rate in effect at each period-end. Statement of Operations amounts are translated at the average rate of exchange prevailing during the period. Translation adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in stockholders’ equity (deficit).
Comprehensive Loss	Comprehensive Loss
	The components of comprehensive loss are net loss and foreign currency translation adjustments for the years ended December 31, 2013 and 2014.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Cash and cash equivalents are stated at cost, which approximates fair market value.  Cash equivalents consist of money market accounts, with fair values estimated based on quoted market prices. Debt balances are stated at historical amounts less principal payments, which approximate fair market value. The Company believes interest rates in its debt agreements are commensurate with lender risk profiles for similar companies.
Advertising Costs	Advertising costs
	The Company markets its services through its advertising activities in trade publications and on the internet. Advertising costs are included in selling and marketing expenses on the statements of operations and are expensed as incurred.  Advertising costs for the years ended December 31, 2013 and 2014 were $16,677 and $62,793, respectively.
Concentration of Credit Risk and Clients and Limited Suppliers	Concentration of Credit Risk Clients and Limited Suppliers
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. At December 31, 2013 and 2014, the Company had $7,726,681 and $1,960,623 in cash and cash equivalents that exceeded federally insured limits. At December 31, 2013 and 2014, $6,969 and $6,571 of cash was held outside of the United States.
	Revenue sources that accounted for greater than 10 percent of revenue are provided below (* indicates amount is below 10%):
		Year Ended December 31,
		2013					2014
				Percent of					Percent of
				Total					Total
		Revenue		Revenue			Revenue		Revenue
	GlaxoSmithKline entities:
	GlaxoSmithKline LLC	$	1,134,366		5.8	%	$	174,597		*	%
	GlaxoSmithKline Biologicals S.A.	$	3,534,619		17.9	%	$	1,287,184		*	%
	Total GlaxoSmithKline entities	$	4,668,985		23.7	%	$	1,461,781		*	%
	Medicare, net of contractual allowances	$	4,521,732		22.8	%	$	4,886,507		29.2	%
	Clients that accounted for greater than 10 percent of gross accounts receivable are provided below (* indicates amount is below 10%):
		As of December 31,
		2013					2014
				Percent of					Percent of
		Receivable		Gross			Receivable		Gross
		Balance		Receivables			Balance		Receivables
	GlaxoSmithKline entities:
	GlaxoSmithKline LLC	$	597,937		6.9	%	$	174,547		*	%
	GlaxoSmithKline Biologicals S.A.	$	544,298		6.3	%	$	588,212		*	%
	Total GlaxoSmithKline entities	$	1,142,235		13.2	%	$	762,759		*	%
	Medicare, net of contractual allowances	$	2,422,611		28.1	%	$	2,814,989		28.5	%
	Many of the supplies and reagents used in the Company’s testing process are procured from a limited number of suppliers. Any supply interruption or an increase in demand beyond the suppliers’ capabilities could have an adverse impact on the Company’s business. Management believes it can identify alternative sources, if necessary, but it is possible such sources may not be identified in sufficient time to avoid an adverse impact on its business. Refer also to Note 6 for further discussion regarding these supply agreements. The Company purchases certain laboratory supplies and reagents primarily from a limited number of suppliers. The Company made approximately 87% of its reagent purchases from four suppliers during the year ended December 31, 2013 and made approximately 73% of its reagent purchases from three suppliers during the year ended December 31, 2014.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which modifies how all entities recognize revenue, and consolidates into one Accounting Standards Codification ("ASC") Topic (ASC Topic 606, Revenue from Contracts with Customers) the current guidance found in ASC Topic 605, Revenue Recognition, and various other revenue accounting standards for specialized transactions and industries. The core principle of the guidance is that “an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” In achieving this objective, an entity must perform five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations of the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 also clarifies how an entity should account for costs of obtaining or fulfilling a contract in a new ASC Subtopic 340-40, Other Assets and Deferred Costs – Contracts with Customers.
	ASU 2014-09 is effective for public companies for annual periods beginning after December 15, 2016 and interim periods within those annual periods, and early adoption is not permitted. ASU 2014-09 may be applied using either a full retrospective approach, in which all years included in the financial statements are presented under the revised guidance, or a modified retrospective approach. Under the modified retrospective cumulative catch-up approach, financial statements will be prepared using the new standard for the year of adoption, but not for prior years. Under this method, entities will recognize a cumulative catch-up adjustment to the opening balance of retained earnings at the effective date for contracts that still require performance by the company and disclose all line items in the year of adoption as if they were prepared under the old revenue guidance. The Company is currently evaluating the impact of ASC 606, but at the current time does not know what impact the new standard will have on revenue recognized and other accounting decisions in future periods, if any, nor what method of adoption will be selected if the impact is material.
	In August 2014, the Financial Accounting Standards Board issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-09”). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there is substantial doubt about a company's ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company's ability to continue as a going concern within one year from the date the financial statements are issued. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter; earlier adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial condition, results of operations or cash flows.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Schedule of ResponseDX Accounts Receivable	ResponseDX® accounts receivable consisted of the following:
		December 31,		December 31,
		2013		2014
	Net Medicare receivable	$	2,422,611	$	2,814,989
	Net Private Payor receivable		4,315,587		6,029,300
			6,738,198		8,844,289
	Allowance for doubtful accounts		-2,404,659		-2,071,706
		$	4,333,539	$	6,772,583
Schedule of Estimated Useful Lives of Property and Equipment	The Company has determined the estimated useful lives of its property and equipment, as follows:
	Laboratory equipment	5 to 7 years
	Furniture and equipment	5 to 7 years
	Purchased and internally-developed software	3 to 5 years
	Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term
Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue	Revenue sources that accounted for greater than 10 percent of revenue are provided below (* indicates amount is below 10%):
		Year Ended December 31,
		2013					2014
				Percent of					Percent of
				Total					Total
		Revenue		Revenue			Revenue		Revenue
	GlaxoSmithKline entities:
	GlaxoSmithKline LLC	$	1,134,366		5.8	%	$	174,597		*	%
	GlaxoSmithKline Biologicals S.A.	$	3,534,619		17.9	%	$	1,287,184		*	%
	Total GlaxoSmithKline entities	$	4,668,985		23.7	%	$	1,461,781		*	%
	Medicare, net of contractual allowances	$	4,521,732		22.8	%	$	4,886,507		29.2	%
Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Schedule of Revenue by Major Customers by Reporting Segments	The following details ResponseDX® revenue for the years ended December 31, 2013 and 2014:
		Year Ended December 31,
		2013		2014
	Net Medicare revenue	$	4,521,732	$	4,886,507
	Net Private Payor revenue		7,489,642		9,709,690
	Net ResponseDX® revenue	$	12,011,374	$	14,596,197
Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Schedule of Revenue by Major Customers by Reporting Segments	Clients that accounted for greater than 10 percent of gross accounts receivable are provided below (* indicates amount is below 10%):
		As of December 31,
		2013					2014
				Percent of					Percent of
		Receivable		Gross			Receivable		Gross
		Balance		Receivables			Balance		Receivables
	GlaxoSmithKline entities:
	GlaxoSmithKline LLC	$	597,937		6.9	%	$	174,547		*	%
	GlaxoSmithKline Biologicals S.A.	$	544,298		6.3	%	$	588,212		*	%
	Total GlaxoSmithKline entities	$	1,142,235		13.2	%	$	762,759		*	%
	Medicare, net of contractual allowances	$	2,422,611		28.1	%	$	2,814,989		28.5	%

Property_and_Equipment_and_Int1

Property and Equipment and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following:
		December 31,		December 31,
		2013		2014
	Laboratory equipment	$	4,468,055	$	4,543,019
	Furniture and equipment		736,886		762,466
	Leasehold improvements		487,843		496,523
			5,692,784		5,802,008
	Less: Accumulated depreciation		-3,758,202		-4,395,603
	Total property and equipment, net	$	1,934,582	$	1,406,405
	Purchased software	$	749,587	$	803,719
	Internally developed software		213,361		213,361
	Trademarks		33,000		33,000
			995,948		1,050,080
	Less: Accumulated amortization		-228,725		-418,931
	Total intangible assets, net	$	767,223	$	631,149
Schedule of Capital Leased Assets	The Company leases certain equipment and related software that is recorded as capital leases. This equipment and software is included in property and equipment on the accompanying balance sheet as of December 31, 2013 and 2014 as follows:
		2013		2014
	Equipment and software financed under capital leases	$	584,150	$	655,467
	Less: Accumulated amortization		-320,769		-472,679
	Equipment and software financed under capital leases, net	$	263,381	$	182,788
Schedule of Future Minimum Lease Payments Under Capital Leases	Future minimum lease payments under capital leases as of December 31, 2014 are as follows:
	Years ending December 31,
	2015	$	129,154
	2016		68,792
	2017		16,364
	2018		16,364
	Thereafter		9,546
	Total minimum lease payments		240,220
	Less amount represented by interest		-35,797
	Less current portion		-100,951
	Capital lease obligation, net of current portion	$	103,472

Loss_Per_Share_Tables

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation for Basic and Diluted Loss Per Share	The following table sets forth the computation for basic and diluted loss per share:
		Year Ended December 31,
		2013		2014
	Numerator:
	Net loss	$	-8,020,515	$	-13,699,362
	Numerator for basic and diluted earnings per share	$	-8,020,515	$	-13,699,362
	Denominator:
	Denominator for basic and diluted earnings per share — weighted-average shares outstanding		33,481,439		38,755,546
	Basic and diluted loss per share	$	-0.24	$	-0.35

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments under Noncancelable Operating Leases
	Future minimum lease payments by year and in the aggregate due under noncancelable operating leases for facilities, equipment and software as a service, consist of the following at December 31, 2014:
	Years Ending December 31,
	2015	$	582,018
	2016		35,807
	Total	$	617,825

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used to Estimate Share-Based Compensation Expense Using Black-Scholes Model	Except for the certain grants of restricted common stock and common stock options containing market conditions as described below, the Company estimated share-based compensation expense for the years ended December 31, 2013 and 2014 using the Black-Scholes model with the following weighted average assumptions:
			Year Ended December 31,
			2013			2014
	Risk free interest rate		0.90-1.77	%		1.78-1.91	%
	Expected dividend yield		—			—
	Expected volatility		102.2-107.4	%		98.4-103.3	%
	Expected term **(in years)		5.0-6.0			5.5-6.0
	Forfeiture rate***		7	%		0% -21	%
	** Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the lack of historical exercises and the standard terms of the employee option grants, including options are granted at-the-money, exercise is conditional only on performing service through the vesting dates, termination of service causes forfeiture of options, employees have a limited number of days to exercise options after termination of service, and options are non-transferable.
	*** Forfeiture range represents 0% for directors and 21% for employees.
Summary of Stock Option Activity	The following table summarizes the stock option activity for the 2000 Stock Plan and the 2006 Stock Plan for the years ended December 31, 2013 and 2014:
						Weighted
						Average			Remaining			Aggregate
			Number of			Exercise			Contractual			Intrinsic
			Shares			Price			Life (Years)			Value
	Outstanding, December 31, 2012			1,749,310		$	2.12			8.32		$	151,919
	Granted			1,115,750			1.33
	Exercised			-18,023			1.33
	Expired			-253,060			2.3
	Forfeited			-305,901			1.39
	Outstanding, December 31, 2013			2,288,076		$	1.83			8.41		$	1,082
	Granted			815,250			0.87
	Exercised			-20,000			1.16
	Expired			-47,923			1.35
	Forfeited			-201,799			1.24
	Outstanding, December 31, 2014			2,833,604			1.62			7.91			-
	Exercisable, December 31, 2014			1,498,929		$	2.07			6.94		$	-
Schedule of Options Outstanding	The following table provides additional information in regards to options outstanding as of December 31, 2014:
				Options Outstanding						Options Exercisable
							Weighted Average						Weighted Average
							Remaining						Remaining
				Number of			Contractual			Number of			Contractual
	Exercise Price			Options			Term			Options			Term
	$	0.67 to 0.99			730,771			9.5			68,635			9.5
		1.00 to 1.99			1,597,331			8.1			956,875			7.8
		2.00 to 2.99			288,002			6.6			255,919			6.5
		3.00 to 3.99			71,000			3.6			71,000			3.6
		4.29			11,500			2.6			11,500			2.6
		7			135,000			2.4			135,000			2.4
					2,833,604			7.9			1,498,929			6.9
Schedule of Stock Based Compensation Included in Results of Operations	Stock-based compensation expense - employees was classified in the results of operations as follows:
			Year Ended December 31,
			2013			2014
	Cost of revenue		$	30,527		$	44,597
	Selling and marketing expense			29,791			36,321
	General and administrative expense			372,158			642,564
	Research and development expense			41,625			52,763
	Totals		$	474,101		$	776,245
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Restricted stock compensation expense – consultants was classified in the results of operations as follows:
			Year Ended December 31,
			2013			2014
	General and administrative expense		$	-		$	86,250
Schedule of Awards to Mr. Bologna	The following table summarizes these awards to Mr. Bologna:
								Intrinsic
								Value as of								Remaining
								December 31,						Options		Contractual
	Type		Grant Date		Number of Awards			2014			Exercise Price			Exercisable		Term
	Restricted Shares of Common Stock		12/21/11			270,000		$	—		$	1.2			—		7
	Options		12/21/11			600,000		$	—		$	1.2			600,000		7
	Options		12/21/11			300,000		$	—		$	1.2			300,000		7

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income Tax Provision	The components of the income tax provision were as follows:
		Year Ended December 31,
		20123		2014
	Current
	Federal	$	—	$	—
	Foreign		—		—
	State		—		—
	Total		—		—
	Deferred
	Federal		—		—
	Foreign		—		—
	State		—		—
			—		—
	Income tax provision	$	—	$	—
Schedule of Loss Before Income Tax Provision	For financial statement purposes, loss before income tax provision includes the following components:
		Year Ended December 31,
		2013		2014
	Domestic	$	-8,012,906	$	-13,691,729
	Foreign		-7,609		-7,633
		$	-8,020,515	$	-13,699,362
Reconciliation of Expected Income Tax Benefit Computed Using Federal Statutory Income Tax Rate	A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate of 34% to the Company’s effective income tax rate is as follows:
		Year Ended December 31,
		2013		2014
	Income tax benefit based on federal statutory rate	$	-2,729,000	$	-4,658,000
	State income tax benefit, net of federal income tax		-413,000		-70,000
	Change in deferred tax valuation allowance		3,048,000		4,478,000
	Stock-based compensation		75,000		203,000
	Foreign net operating loss		-		—
	Other, net		19,000		47,000
	Income tax provision	$	—	$	—
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and deferred tax liabilities are presented below:
		December 31,		December 31,
		2013		2014
	Deferred tax assets:
	Domestic net operating loss carryforwards	$	15,627,000	$	20,598,000
	Foreign net operating loss carryforwards		800,000		802,000
	Deferred revenue		-		—
	Federal and state tax credit		297,000		297,000
	Stock-based compensation		682,000		803,000
	Capitalized costs		1,232,000		1,164,000
	Other, net		2,129,000		1,581,000
	Total gross deferred tax assets		20,767,000		25,245,000
	Less valuation allowance on deferred tax assets		-20,767,000		-25,245,000
	Net deferred taxes		—		—
	Deferred tax liabilities:
	Plant and equipment, principally accelerated depreciation		—		—
	Total deferred tax liabilities		—		—
	Net deferred taxes	$	—	$	—

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Financial Information by Geographic Area	The following tables contain certain financial information by geographic area:
		Year Ended December 31,
		2013		2014
	Revenue: (Customer geographic location)
	United States	$	15,219,155	$	15,335,888
	Europe		3,556,354		1,322,669
	Other International		1,028,850		61,770
		$	19,801,359	$	16,720,327
		December 31,		December 31,
		2013		2014
	Long-lived assets:
	United States	$	2,681,666	$	2,037,554
		$	2,681,666	$	2,037,554

Offerings_of_Common_Stock_Tabl

Offerings of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Schedule of Common Stock Classified Outside of Stockholders' Equity	Activity in common stock classified outside of stockholders’ equity (deficit) was as follows:
		Number of	Amount
		Shares
	Balance, January 1, 2013	9,561,847	$	11,775,724
	Issuance of common stock classified outside of stockholders’ equity (deficit)	—		—
	Reclassification to stockholders’ equity (deficit)	-4,561,847		-6,275,724
	Balance, December 31, 2013	5,000,000	$	5,500,000
	Issuance of common stock classified outside of stockholders’ equity (deficit)	—		—
	Reclassification to stockholders’ equity (deficit)	-5,000,000		-5,500,000
	Balance, December 31, 2014	—	$	—

Organization_Operations_and_Ba1

Organization, Operations and Basis of Accounting (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation And Presentation Of Financial Statements [Line Items]
Accumulated deficit	($78,996,541)	($65,297,179)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	2 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended
	Mar. 07, 2013	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 09, 2014	Sep. 30, 2014	Jul. 30, 2014	Jul. 31, 2014	Aug. 31, 2013	Feb. 03, 2015	Jan. 30, 2015
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		$7,810,417		$7,810,417	$7,810,417	$6,225,923
Allowance for doubtful accounts		2,071,706		2,071,706	2,071,706	2,404,659					257,000
Revenue from pharmaceutical clients					2,124,130	7,789,985
Line of credit, expiration date	7-Mar-15
Line of credit, borrowing base percentage of pharmaceutical accounts receivable		80.00%		80.00%	80.00%
Line of credit, interest above prime rate						1.00%
Line of credit, interest charged				5.50%	5.00%
Line of credit, amount drawn		1,500,000		1,500,000	1,500,000	1,000,000
Advertising costs					62,793	16,677
Payment period from the date of invoice	45 days
Cash and cash equivalents that exceeded federally insured limits		1,960,623		1,960,623	1,960,623	7,726,681
Payments for Fees					40,000
Loans Receivable, Description of Variable Rate Basis					2.25%
Bad debt expense					5,842,212	3,165,918
Line of Credit Facility, Initiation Date					14-Jul-11
Cash, Uninsured Amount		6,571		6,571	6,571	6,969
Line of Credit Facility, Maximum Borrowing Capacity							8,500,000		2,000,000
Adjustments to Additional Paid in Capital, Warrant Issued					377,140
Additional allowance for accounts receivable						690,000
Allowance For Doubtful Accounts Percentage Of Accounts Receivable		100.00%		100.00%	100.00%
Compensating Balance, Amount		4,000,000		4,000,000	4,000,000
Royalty Expense		240,077	240,077		480,154
Cost of Revenue					437,865
Licensing Agreements [Member]
Significant Accounting Policies [Line Items]
License Costs					42,289	305,616
Initial Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							681,090		681,090
Fair value Of Warrants Issued							377,140		377,140
Conversion of Stock Conversion Price Per Share								$0.55	$0.55
Fair Value Assumptions, Risk Free Interest Rate								2.01%	2.01%
Fair Value Assumptions, Expected Dividend Rate								0.00%	0.00%
Fair Value Assumptions, Expected Volatility Rate								101.50%	101.50%
Fair Value Assumptions, Expected Term							6 years			6 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.94					$0.94	$0.94
First Amendment Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							576,923
Class of Warrant or Right, Exercise Price of Warrants or Rights							$0.39
SG Financial LLC [Member] | Initial Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							200,321
Subsequent Event [Member]
Significant Accounting Policies [Line Items]
Line of Credit Facility, Commitment Fee Amount					750,000
Line of Credit Facility, Remaining Borrowing Capacity		2,000,000		2,000,000	2,000,000
Line of Credit Facility, Commitment Fee Percentage					15.00%
Subsequent Event [Member] | Initial Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												681,090
Class of Warrant or Right, Exercise Price of Warrants or Rights												$0.94
Subsequent Event [Member] | First Amendment Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												576,923	576,923
Class of Warrant or Right, Exercise Price of Warrants or Rights												$0.39	$0.39
Subsequent Event [Member] | SG Financial LLC [Member] | Initial Warrant [Member]
Significant Accounting Policies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													200,321
Maximum [Member]
Significant Accounting Policies [Line Items]
Line of credit, fee for unused portion					0.38%
Minimum [Member]
Significant Accounting Policies [Line Items]
Line of credit, fee for unused portion					0.25%
SWK Credit Agreement [Member]
Significant Accounting Policies [Line Items]
Long-term Debt, Gross									12,000,000
Line of Credit Facility, Interest Rate Description					The Loan bears interest at a rate equal to the LIBOR Rate (as defined in the SWK Credit Agreement) plus an applicable margin of 12.5% per annum, subject to a one percent (1.0%) LIBOR floor. Interest on the Loan is due and payable in arrears (i) on the forty-fifth
Line of Credit Facility, Current Borrowing Capacity							2,500,000
Line of Credit Facility, Commitment Fee Amount							1,029,412
Loans Payable		8,500,000		8,500,000	8,500,000
Debt Issuance Cost					576,161
Adjustments to Additional Paid in Capital, Warrant Issued					377,140
Deferred Finance Costs, Net		187,092		187,092	187,092
SWK Credit Agreement [Member] | Subsequent Event [Member]
Significant Accounting Policies [Line Items]
Line of Credit Facility, Current Borrowing Capacity		10,000,000		10,000,000	10,000,000
Line of Credit Facility, Increase (Decrease), Net					1,500,000
Medicare Program [Member]
Significant Accounting Policies [Line Items]
Percentage Of Revenue					38.00%	33.50%
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage					73.00%	87.00%
Roche Molecular Systems [Member]
Significant Accounting Policies [Line Items]
Royalty Expense					211,932	280,325
Clinical [Member]
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		1,037,834		1,037,834	1,037,834	1,892,384
Payment period from the date of invoice					45 days
ResponseDX [Member]
Significant Accounting Policies [Line Items]
Allowance for doubtful accounts		2,071,706		2,071,706	2,071,706	2,404,659
Bad debt expense					5,842,212	3,165,918
Silicon Valley Bank [Member]
Significant Accounting Policies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		500,000		500,000	500,000	1,000,000
Line of Credit Facility, Capacity Available for Trade Purchases		12,000,000		12,000,000	12,000,000
Line Of Credit Facility Covenant Compliance Liquidity Amount		1,000,000
Silicon Valley Bank [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Adjusted Quick Ratio					1.25
Silicon Valley Bank [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Adjusted Quick Ratio					$1

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Schedule of ResponseDX Accounts Receivable) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2013
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Allowance for doubtful accounts	($2,071,706)	($2,404,659)	($257,000)
Total	7,810,417	6,225,923
ResponseDX [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Accounts receivable	8,844,289	6,738,198
Allowance for doubtful accounts	-2,071,706	-2,404,659
Total	6,772,583	4,333,539
ResponseDX [Member] | Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Accounts receivable	2,814,989	2,422,611
Private Payor [Member] | ResponseDX [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Accounts receivable	$6,029,300	$4,315,587

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Schedule of Estimated Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Purchased And Internally Developed Software Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] | Purchased And Internally Developed Software Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Schedule of ResponseDX Revenue) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net ResponseDX B. revenue	$16,720,327	$19,801,359
ResponseDX [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net ResponseDX B. revenue	14,596,197	12,011,374
Private Payor [Member] | ResponseDX [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net ResponseDX B. revenue	9,709,690	7,489,642
Medicare [Member] | ResponseDX [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net ResponseDX B. revenue	$4,886,507	$4,521,732

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$16,720,327		$19,801,359
GlaxoSmithKline LLC [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	174,597		1,134,366
Percent of Total Revenue	0.00%	[1]	5.80%
GlaxoSmithKline Biologicals S.A. [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	1,287,184		3,534,619
Percent of Total Revenue	0.00%	[1]	17.90%
GlaxoSmithKline Entities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	1,461,781		4,668,985
Percent of Total Revenue	0.00%	[1]	23.70%
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$4,886,507		$4,521,732
Percent of Total Revenue	29.20%		22.80%
[1]	indicates amount is below 10%

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Schedule of Customers that Account for Greater than 10 Percent of Accounts Receivable) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Receivable Balance	7,810,417		6,225,923
GlaxoSmithKline LLC [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percent of Total Receivables	0.00%	[1]	5.80%
GlaxoSmithKline LLC [Member] | Accounts Receivable [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Receivable Balance	174,547		597,937
Percent of Total Receivables	0.00%	[1]	6.90%
GlaxoSmithKline Biologicals S.A. [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percent of Total Receivables	0.00%	[1]	17.90%
GlaxoSmithKline Biologicals S.A. [Member] | Accounts Receivable [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Receivable Balance	588,212		544,298
Percent of Total Receivables	0.00%	[1]	6.30%
GlaxoSmithKline Entities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percent of Total Receivables	0.00%	[1]	23.70%
GlaxoSmithKline Entities [Member] | Accounts Receivable [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Receivable Balance	762,759		1,142,235
Percent of Total Receivables	0.00%	[1]	13.20%
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percent of Total Receivables	29.20%		22.80%
Medicare [Member] | Accounts Receivable [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Receivable Balance	2,814,989		2,422,611
Percent of Total Receivables	28.50%		28.10%
[1]	indicates amount is below 10%

Property_and_Equipment_and_Int2

Property and Equipment and Intangible Assets (Details) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 23, 2013
Property, Plant and Equipment [Line Items]
Amortization Expenses	$827,609	$632,975
Payments to Acquire Property, Plant, and Equipment	0	200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	257,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment	785,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	138,000
Property, Plant and Equipment, Useful Life	5 years
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2015	193,926
2016	179,887
2017	160,028
2018	59,413
Thereafter	4,895
Pathwork [Member]
Property, Plant and Equipment [Line Items]
Stock Issued During Period, Shares, Purchase of Assets			500,000
Payments to Acquire Property, Plant, and Equipment			$200,000

Property_and_Equipment_and_Int3

Property and Equipment and Intangible Assets (Schedule of Property and Equipment and Intangible Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$5,802,008	$5,692,784
Less: Accumulated depreciation	-4,395,603	-3,758,202
Total property and equipment, net	1,406,405	1,934,582
Intangible assets	1,050,080	995,948
Less: Accumulated amortization	-418,931	-228,725
Total intangible assets, net	631,149	767,223
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Intangible assets	803,719	749,587
Trademarks [Member]
Property, Plant and Equipment [Line Items]
Intangible assets	33,000	33,000
Internally developed software [Member]
Property, Plant and Equipment [Line Items]
Intangible assets	213,361	213,361
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,543,019	4,468,055
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	762,466	736,886
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$496,523	$487,843

Property_and_Equipment_and_Int4

Property and Equipment and Intangible Assets (Schedule of Capital Leased Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Equipment and software financed under capital leases	$655,467	$584,150
Less: Accumulated amortization	-472,679	-320,769
Equipment and software financed under capital leases, net	$182,788	$263,381

Property_and_Equipment_and_Int5

Property and Equipment and Intangible Assets (Schedule of Future Minimum Lease Payments under Capital Leases) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Years ending December 31, 2015	$129,154
Years ending December 31, 2016	68,792
Years ending December 31, 2017	16,364
Years ending December 31, 2018	16,364
Years ending Thereafter	9,546
Total minimum lease payments	240,220
Less amount represented by interest	-35,797
Less current portion	100,951	157,238
Capital lease obligation, net of current portion	$103,472	$136,419

Loss_Per_Share_Details

Loss Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Number of shares excluded from the calculation of diluted loss per share	2,833,604	2,288,076
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	270,000
Warrants and Rights Outstanding	$681,090

Loss_Per_Share_Computation_for

Loss Per Share (Computation for Basic and Diluted Loss Per Share) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss	($13,699,362)	($8,020,515)
Numerator for basic and diluted earnings per share	($13,699,362)	($8,020,515)
Denominator:
Denominator for basic and diluted earnings per share - weighted-average shares outstanding	38,755,546	33,481,439
Basic and diluted loss per share	($0.35)	($0.24)

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments And Contingencies Disclosure [Line Items]
Rent expense	$841,309	$683,926
California State [Member]
Commitments And Contingencies Disclosure [Line Items]
Operating leases, space	27,446
Operating lease expiration date	30-Jun-15
Maryland [Member]
Commitments And Contingencies Disclosure [Line Items]
Operating lease expiration date	31-Jan-13

Commitments_and_Contingencies_2

Commitments and Contingencies (Schedule of Future Minimum Lease Payments under Noncancelable Operating Leases) (Details) (USD $)	Dec. 31, 2014
Commitments And Contingencies Disclosure [Line Items]
2015	$582,018
2016	35,807
Total	$617,825

License_and_Collaborative_Agre1

License and Collaborative Agreements (Details) (USD $)	3 Months Ended		12 Months Ended		1 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty expense included in cost of revenue	$240,077	$240,077	$480,154
Revenue, Net, Total			16,720,327	19,801,359
Cost of Revenue			437,865
Shanghai BioChip Company, Ltd. [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Agreement, Termination Notice Period			90 days
Revenue recognized			35,027	48,948
Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized					1,500,000
License and Services Revenue	240,077	240,077	480,154
Licensing Agreements [Member] | University of Southern California [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty expense included in cost of revenue			42,289	305,616
Licensing Agreements [Member] | Roche Molecular Systems [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty expense included in cost of revenue			211,932	280,325
Licensing Agreements [Member] | Glaxo, Smith, Kline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized				1,000,000
Service Agreements [Member] | Glaxo, Smith, Kline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue, Net, Total			174,597	1,134,366
Service Agreements [Member] | Taiho Pharmaceutical Co., Ltd. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue, Net, Total			0	950,000
Service Agreements [Member] | GSK Bio [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue, Net, Total			$1,287,184	$3,534,619
Collaborative Agreement, Termination Notice Period			90 days

Stock_Option_Plans_Details

Stock Option Plans (Details) (USD $)	12 Months Ended				1 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Mar. 31, 2000	Dec. 31, 2008	Mar. 31, 2012	Dec. 31, 2012	Oct. 26, 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, number of common stock shares	815,250		1,115,750
Options outstanding, weighted average exercise price	$1.62		$1.83					2.12
Non-vested stock options outstanding, Weighted average grant date fair value	$0.86
Stock options granted, average fair value	$0.70		$1.07
Number of restricted common stock granted	270,000
Stock option granted, exercise price	$0.87		$1.33
Share-based compensation	$776,245		$474,101
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	2,833,604		2,288,076					1,749,310
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	0		1,082					151,919
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.70		$1.07
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Forfeiture Rate			7.00%	[1]
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted, average fair value	$0.32
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	7,605
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.32
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Forfeiture Rate	21.00%	[1]
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Forfeiture Rate	0.00%	[1]
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted common stock granted	270,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	300,000
Non-employee option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	3 years
Non-employee option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	2 years
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration period	10 years
Stock Option Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized									210,000
Stock option granted, number of common stock shares					1,600,000
Other Stock Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, number of common stock shares					16,000
2006 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	3,770,000								2,160,000
Increase in the number of shares available for issuance	210,000					200,000
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted	886,906
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	778,123
Percentage Of Common Stock Outstanding	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	1,334,675
Thomos Bologna [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	168,149		178,122
Thomos Bologna [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted common stock granted	270,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	300,000
Thomos Bologna [Member] | Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average closing price of common stock	$2.40
Number of days, for calculating average closing price of common stock	30 days
Thomos Bologna [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	36 months
Share-based compensation							$129,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								300,000
Common Stock, Average Closing Price	$1.80
Thomos Bologna [Member] | Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	36 months
Thomos Bologna [Member] | Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	18 months
Average closing price of common stock	$1.80
Number of days, for calculating average closing price of common stock	30 days
Thomos Bologna [Member] | Stock Option [Member] | Period One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, number of common stock shares	600,000
Stock option granted, exercise price	$1.20
Thomos Bologna [Member] | Stock Option [Member] | Period Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, number of common stock shares	300,000
[1]	Forfeiture range represents 0% for directors and 21% for employees

Stock_Option_Plans_Schedule_of

Stock Option Plans (Schedule of Assumptions Used to Estimate Share-Based Compensation Expense Using Black-Scholes Model) (Details)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%		0.00%
Forfeiture rate			7.00%	[1]
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.91%		1.77%
Expected volatility	103.30%		107.40%
Expected term (in years)	6 years	[2]	6 years	[2]
Forfeiture rate	21.00%	[1]
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.78%		0.90%
Expected volatility	98.40%		102.20%
Expected term (in years)	5 years 6 months	[2]	5 years	[2]
Forfeiture rate	0.00%	[1]
[1]	Forfeiture range represents 0% for directors and 21% for employees
[2]	Expected term is calculated using SAB 107, Simplified Formula. Management has concluded that the use of the simplified method for calculating the expected term of its common stock option grants is appropriate given the lack of historical exercises and the standard terms of the employee option grants, including options are granted at-the-money, exercise is conditional only on performing service through the vesting dates, termination of service causes forfeiture of options, employees have a limited number of days to exercise options after termination of service, and options are non-transferable.

Stock_Option_Plans_Summary_of_

Stock Option Plans (Summary of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Shares
Outstanding, December 31, 2013	2,288,076	1,749,310
Granted	815,250	1,115,750
Exercised	-20,000	-18,023
Expired	-47,923	-253,060
Forfeited	-201,799	-305,901
Outstanding, December 31, 2014	2,833,604	2,288,076	1,749,310
Exercisable, December 31, 2014	1,498,929
Weighted Average Exercise Price
Outstanding, December 31, 2013	$1.83	$2.12
Granted	$0.87	$1.33
Exercised	$1.16	$1.33
Expired	$1.35	$2.30
Forfeited	$1.24	$1.39
Outstanding, December 31, 2014	$1.62	$1.83	$2.12
Exercisable, December 31, 2014	$2.07
Remaining Contractual Life (Years)
Outstanding, December 31, 2013	7 years 10 months 28 days	8 years 4 months 28 days	8 years 3 months 25 days
Exercisable, December 31, 2014	6 years 11 months 8 days
Aggregate Intrinsic Value
Outstanding, December 31,2013	$1,082	$151,919
Outstanding, December 31, 2014	0	1,082	151,919
Exercisable, December 31, 2014	$0

Stock_Option_Plans_Schedule_of1

Stock Option Plans (Schedule of Options Outstanding) (Details)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	2,833,604
Options Outstanding Weighted Average Remaining Contractual Term	7 years 10 months 24 days
Options Exercisable Number of Options	1,498,929
Options Exercisable Weighted Average Remaining Contractual Term	6 years 10 months 24 days
$ 0.67 to 0.99 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	730,771
Options Outstanding Weighted Average Remaining Contractual Term	9 years 6 months
Options Exercisable Number of Options	68,635
Options Exercisable Weighted Average Remaining Contractual Term	9 years 6 months
$ 1.00 to 1.99 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	1,597,331
Options Outstanding Weighted Average Remaining Contractual Term	8 years 1 month 6 days
Options Exercisable Number of Options	956,875
Options Exercisable Weighted Average Remaining Contractual Term	7 years 9 months 18 days
$ 2.00 to 2.99 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	288,002
Options Outstanding Weighted Average Remaining Contractual Term	6 years 7 months 6 days
Options Exercisable Number of Options	255,919
Options Exercisable Weighted Average Remaining Contractual Term	6 years 6 months
$ 3.00 to 3.99 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	71,000
Options Outstanding Weighted Average Remaining Contractual Term	3 years 7 months 6 days
Options Exercisable Number of Options	71,000
Options Exercisable Weighted Average Remaining Contractual Term	3 years 7 months 6 days
$ 4.29 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	11,500
Options Outstanding Weighted Average Remaining Contractual Term	2 years 7 months 6 days
Options Exercisable Number of Options	11,500
Options Exercisable Weighted Average Remaining Contractual Term	2 years 7 months 6 days
$ 7 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding Number of Options	135,000
Options Outstanding Weighted Average Remaining Contractual Term	2 years 4 months 24 days
Options Exercisable Number of Options	135,000
Options Exercisable Weighted Average Remaining Contractual Term	2 years 4 months 24 days

Stock_Option_Plans_Schedule_of2

Stock Option Plans (Schedule of Stock-Based Compensation Included in Results of Operations) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$776,245	$474,101
Cost of revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	44,597	30,527
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	52,763	41,625
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	36,321	29,791
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$642,564	$372,158

Stock_Option_Plans_Schedule_of3

Stock Option Plans (Schedule of Restricted stock Compensation Included in Results of Operations) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
General and administrative expense	$86,250	$0

Stock_Option_Plans_Schedule_of4

Stock Option Plans (Schedule of Awards to Mr. Bologna) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Awards	270,000
Exercise Price	$2.07
Options Exercisable	1,498,929
Remaining Contractual Term	7 years 10 months 28 days	8 years 4 months 28 days	8 years 3 months 25 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	21-Dec-11
Number of Awards	270,000
Intrinsic Value	$0
Exercise Price	$1.20
Options Exercisable	0
Remaining Contractual Term	7 years
Thomos Bologna [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Awards	270,000
Employee Stock Option [Member] | Thomos Bologna [Member] | Period One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	21-Dec-11
Number of Awards	600,000
Intrinsic Value	0
Exercise Price	$1.20
Options Exercisable	600,000
Remaining Contractual Term	7 years
Employee Stock Option [Member] | Thomos Bologna [Member] | Period Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	21-Dec-11
Number of Awards	300,000
Intrinsic Value	$0
Exercise Price	$1.20
Options Exercisable	300,000
Remaining Contractual Term	7 years

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%
Minimum [Member]
Open Tax Year	2003
Maximum [Member]
Open Tax Year	2013
Domestic Tax Authority [Member]
Operating Loss Carryforwards	54
Beginning year of expiration of net operating loss carryforwards	2021
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	41
Beginning year of expiration of net operating loss carryforwards	2015
Foreign Tax Authority [Member]
Operating Loss Carryforwards	3

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Tax Provision) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current
Federal	$0	$0
Foreign	0	0
State	0	0
Total	0	0
Deferred
Federal	0	0
Foreign	0	0
State	0	0
Total	0	0
Income tax provision	$0	$0

Income_Taxes_Schedule_of_Loss_

Income Taxes (Schedule of Loss Before Income Tax Provision) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Examination [Line Items]
Domestic	($13,691,729)	($8,012,906)
Foreign	-7,633	-7,609
Loss before income tax provision	($13,699,362)	($8,020,515)

Income_Taxes_Reconciliation_of

Income Taxes (Reconciliation of Expected Income Tax Benefit Computed Using Federal Statutory Income Tax Rate) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Examination [Line Items]
Income tax benefit based on federal statutory rate	($4,658,000)	($2,729,000)
State income tax benefit, net of federal income tax	-70,000	-413,000
Change in deferred tax valuation allowance	4,478,000	3,048,000
Stock-based compensation	203,000	75,000
Foreign net operating loss	0	0
Other, net	47,000	19,000
Income tax provision	$0	$0

Income_Taxes_Schedule_of_Defer

Income Taxes (Schedule of Deferred Tax Assets and Deferred Tax Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Domestic net operating loss carryforwards	$20,598,000	$15,627,000
Foreign net operating loss carryforwards	802,000	800,000
Deferred revenue	0	0
Federal and state tax credit	297,000	297,000
Stock-based compensation	803,000	682,000
Capitalized costs	1,164,000	1,232,000
Other, net	1,581,000	2,129,000
Total gross deferred tax assets	25,245,000	20,767,000
Less valuation allowance on deferred tax assets	-25,245,000	-20,767,000
Net deferred taxes	0	0
Deferred tax liabilities:
Plant and equipment, principally accelerated depreciation	0	0
Total deferred tax liabilities	0	0
Net deferred taxes	$0	$0

Segment_Information_Details

Segment Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenue	$16,720,327	$19,801,359
Long-lived assets	2,037,554	2,681,666
United States [Member]
Segment Reporting Information [Line Items]
Net revenue	15,335,888	15,219,155
Long-lived assets	2,037,554	2,681,666
Europe [Member]
Segment Reporting Information [Line Items]
Net revenue	1,322,669	3,556,354
Other International [Member]
Segment Reporting Information [Line Items]
Net revenue	$61,770	$1,028,850

Offerings_of_Common_Stock_Deta

Offerings of Common Stock (Details) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Sep. 09, 2014

Sep. 30, 2014

Jul. 30, 2014

Jul. 31, 2014

Feb. 28, 2015

Jan. 30, 2015

Feb. 02, 2012

Sep. 30, 2012

Jun. 30, 2014

Dec. 31, 2012

Dec. 31, 2013

Aug. 23, 2013

Sep. 30, 2013

Feb. 03, 2015

Subsidiary, Sale of Stock [Line Items]

Net proceeds from issuance of common stock

$0

$6,571,324

Common stock classified outside of stockholders equity (deficit)

0

5,500,000

5,500,000

Payments to Acquire Property, Plant, and Equipment, Total

0

200,000

Initial Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

681,090

681,090

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.94

$0.94

Class Of Warrant Or Rights Date Upto Which Warrants Or Rights Exercisable

30-Jul-20

30-Jul-20

Fair value Of Warrants Issued

377,140

377,140

Conversion of Stock Conversion Price Per Share

$0.55

$0.55

Fair Value Assumptions, Risk Free Interest Rate

2.01%

2.01%

Fair Value Assumptions, Expected Dividend Rate

0.00%

0.00%

Fair Value Assumptions, Expected Volatility Rate

101.50%

101.50%

Fair Value Assumptions, Expected Term

6 years

6 years

First Amendment Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

576,923

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.39

Subsequent Event [Member] | Initial Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

681,090

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.94

Subsequent Event [Member] | First Amendment Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

576,923

576,923

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.39

$0.39

Class Of Warrant Or Rights Date Upto Which Warrants Or Rights Exercisable

3-Feb-21

3-Feb-21

Subsequent Event [Member] | Replacement Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

681,090

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.39

$0.39

Class Of Warrant Or Rights Date Upto Which Warrants Or Rights Exercisable

30-Jul-20

30-Jul-20

SWK Credit Agreement [Member]

Subsidiary, Sale of Stock [Line Items]

Long-term Debt, Gross

12,000,000

SWK Credit Agreement [Member] | Subsequent Event [Member]

Subsidiary, Sale of Stock [Line Items]

Loans Payable

8,500,000

8,500,000

Line of Credit Facility, Increase (Decrease), Net

1,500,000

Line of Credit Facility, Current Borrowing Capacity

2,500,000

10,000,000

SG Financial LLC [Member] | Initial Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

200,321

SG Financial LLC [Member] | Subsequent Event [Member] | Initial Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

200,321

Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Common stock classified outside of stockholders equity (deficit)

0

5,500,000

11,775,724

5,500,000

Shares of common stock reclassified to equity

-5,000,000

-4,561,847

Shares classified outside of stockholders equity

0

5,000,000

9,561,847

5,000,000

Stock Issued During Period, Shares, New Issues

5,897,248

Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

Common stock issued, price per share

$1.50

$1.10

Registration statement filing period after closing of Private Placement

90 days

45 days

Registration statement effective period after closing of Private Placement

180 days

180 days

Percentage of shares purchased required to be held for board observer designation right

50.00%

Stock Issued During Period, Value, Purchase of Assets

5,257,267

Stock Issued During Period, Shares, New Issues

8,000,000

September 2012 Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

Common stock classified outside of stockholders equity (deficit)

0

5,500,000

5,500,000

Shares of common stock reclassified to equity

5,000,000

3,000,000

Shares classified outside of stockholders equity

8,000,000

December 2013 Underwritten Public Offering [Member]

Subsidiary, Sale of Stock [Line Items]

Net proceeds from issuance of common stock

4,800,000

5,357,332

Share Price

$1.20

$1.20

Stock Issued During Period, Shares, New Issues

4,464,443

Underwriting Discount Percentage

5.00%

September 2013 Registered Direct Offering [Member]

Subsidiary, Sale of Stock [Line Items]

Common Stock Offering Costs

1,700,000

Pathwork Purchase Agreement [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, Purchase of Assets

500,000

Share Price

$1.96

Stock Issued During Period, Value, Purchase of Assets

980,000

Payments to Acquire Property, Plant, and Equipment, Total

200,000

Registered Direct Offering [Member]

Subsidiary, Sale of Stock [Line Items]

Net proceeds from issuance of common stock

$1,912,250

Share Price

$2.05

Stock Issued During Period, Shares, New Issues

932,805

Offerings_of_Common_Stock_Sche

Offerings of Common Stock (Schedule of Common Stock Classified Outside of Stockholders' Equity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Amount
Ending balance	$0	$5,500,000
Common Stock [Member]
Number of Shares
Beginning balance	5,000,000	9,561,847
Issuance of common stock classified outside of stockholdersb equity (deficit)	0	0
Reclassification to stockholdersb equity (deficit)	-5,000,000	-4,561,847
Ending Balance	0	5,000,000
Amount
Beginning balance	5,500,000	11,775,724
Issuance of common stock classified outside of stockholdersb equity (deficit)	0	0
Reclassification to stockholdersb equity (deficit)	-5,500,000	-6,275,724
Ending balance	$0	$5,500,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

2 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Mar. 07, 2013

Sep. 09, 2014

Jul. 31, 2014

Dec. 31, 2014

Feb. 28, 2015

Jan. 30, 2015

Dec. 19, 2014

Jul. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Feb. 03, 2015

Subsequent Event [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

8,500,000

$2,000,000

Line of Credit Facility, Expiration Date

7-Mar-15

Share Bid Price

$1

Stockholders Equity Attributable to Parent, Total

-1,170,107

2,500,000

5,758,951

-542,211

Initial Warrant [Member]

Subsequent Event [Line Items]

Class Of Warrant Or Rights Date Upto Which Warrants Or Rights Exercisable

30-Jul-20

30-Jul-20

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

681,090

681,090

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.94

$0.94

First Amendment Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

576,923

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.39

SWK Credit Agreement [Member]

Subsequent Event [Line Items]

Line of Credit, Current

1,500,000

SG Financial LLC [Member] | Initial Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

200,321

Subsequent Event [Member]

Subsequent Event [Line Items]

Line of Credit Facility, Commitment Fee Amount

750,000

Subsequent Event [Member] | Initial Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

681,090

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.94

Subsequent Event [Member] | First Amendment Warrant [Member]

Subsequent Event [Line Items]

Class Of Warrant Or Rights Date Upto Which Warrants Or Rights Exercisable

3-Feb-21

3-Feb-21

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

576,923

576,923

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.39

$0.39

Subsequent Event [Member] | Replacement Warrant [Member]

Subsequent Event [Line Items]

Class Of Warrant Or Rights Date Upto Which Warrants Or Rights Exercisable

30-Jul-20

30-Jul-20

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

681,090

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.39

$0.39

Subsequent Event [Member] | SWK Credit Agreement [Member]

Subsequent Event [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

12,000,000

Line of Credit Facility, Commitment Fee Amount

2,000,000

1,029,412

Line of Credit Facility, Current Borrowing Capacity

2,500,000

10,000,000

Line of Credit Facility, Increase (Decrease), Net

1,500,000

Line of Credit Facility, Expiration Date

30-Jul-20

Loans Payable

8,500,000

$8,500,000

Line of Credit Facility, Description

The remaining $2,000,000 of the Loan Commitment Amount (the “Subsequent Term Loan”) may be advanced to the Company upon written request to the Agent during the period beginning on the Amendment Closing Date and ending February 28, 2016 provided

Subsequent Event [Member] | SG Financial LLC [Member] | Initial Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

200,321

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$2,404,659	$991,990
Additions Charged to Costs and Expenses	5,842,212	3,165,918
Deductions	-6,175,165	-1,753,249
Balance at End of Period	$2,071,706	$2,404,659